Exhibit
10.1


 


CERTAIN
CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS “[***]”) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.


 


WESTERN
MAGNESIUM CORP.


 


SECURITIES
PURCHASE AGREEMENT


 


(Convertible
Debenture)


 


THE
Convertible Debenture BEING OFFERED FOR SALE MAY BE PURCHASED BY RESIDENTS OF THE UNITED
STATES PURSUANT TO AVAILABLE EXEMPTIONS UNDER APPLICABLE SECURITIES LEGISLATION.


 


INSTRUCTIONS


 


	1.	Complete
    and sign the Execution Pages of the Securities Purchase Agreement.
	 	 
	2.	Complete
    and sign Schedule A attached to the Securities Purchase Agreement (Information Sheet).
	 	 
	3.	Complete
    and sign Appendix A to Schedule A attached to the Securities Purchase Agreement (the TSX Venture Exchange Form 4C – Corporate
    Placee Registration Form) if you are a non-individual purchaser (including a corporation or a partnership) and hold, or will
    hold upon completion of the Offering, more than 5% of the issued and outstanding Common Stock of the Company on either an Undiluted
    or Diluted(1) basis (unless you have previously filed this form with the TSX Venture Exchange and represent and warrant
    that there has been no change to any of the information in the previously filed form up to the date of the Securities Purchase Agreement)
	 	 
	4.	Complete
    Schedule B attached to the Securities Purchase Agreement (Registration and Delivery Instructions), if required.
	 	 
	5.	Complete
    and sign the Schedule C attached to the Securities Purchase Agreement (Outside of Canada Purchaser Certificate).
	 	 
	6.	If
    you or the beneficial purchaser for whom you are contracting hereunder are a U.S. Person, you must complete and sign Schedule D attached
    to the Securities Purchase Agreement (Certification of U.S. Purchaser) and Appendix A (Certificate of U.S. Person) attached thereto.


 


Payment
Instructions:


 


Please
refer to the payment instructions set forth in Exhibit C hereto.


 





 



1
“Undiluted” means the total number of Common Stock held by a beneficial holder on Closing of the Offering (including
any Common Stock purchased under the Offering); and “Diluted” means the undiluted figure for a beneficial holder plus
any Common Stock which would be issued to that beneficial holder on Closing if all Warrants and Convertible Debentures issued to such
beneficial holder under the Offering were exercised or converted, as the case may be, on Closing.


 




    	(i)



     


    

 


SECURITIES
PURCHASE AGREEMENT


 


This
Securities Purchase Agreement (this “Agreement”) is dated as of April 14, 2022, between Western Magnesium Corp., a
Delaware corporation, and includes any successor company thereto (the “Company”), and the purchasers identified on
the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively the
“Purchasers”).


 


WHEREAS,
the Company and the Purchasers desire to enter into this Agreement, pursuant to which the Purchasers are to be granted the right to acquire
securities of the Company as set forth herein and


 


WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to British Columbia Instrument 72-503 Distribution of
Securities Outside British Columbia and Section 4(a)(2) of the Securities Act, and Rule 506 promulgated thereunder, the Company desires
to issue and sell to the Purchasers, and the Purchasers desire to purchase from the Company, securities of the Company as more fully
described in this Agreement (the “Offering”).


 


NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, the Company and the Purchasers agree as follows:


 


ARTICLE
I.


DEFINITIONS


 


1.1
Definitions. In addition to the terms defined elsewhere in this Agreement: (a) capitalized terms that are not otherwise defined
herein have the meanings given to such terms in the Convertible Debenture (as defined herein), and (b) the following terms have the meanings
set forth in this Section 1.1:


 


“Acquiring
Person” shall have the meaning ascribed to such term in Section 4.7.


 


“Action”
shall have the meaning ascribed to such term in Section 3.1(j).


 


“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.


 


“Applicable
Law” shall mean any law, rule or regulation of any governmental authority or jurisdiction applicable to any party to this Agreement,
as the case may be.


 


“BCSC”
means the British Columbia Securities Commission.


 


“Board
of Directors” means the board of directors of the Company.


 


“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or a provincial
legal holiday in the Province of British Columbia or any day on which banking institutions in the State of New York or the Province of
British Columbia are required by law or other governmental action to close.


 


“Buy-In”
shall have the meaning ascribed to such term in Section 4.1(h).


 


“Closing”
means the delivery and sale of the Convertible Debenture and payment of the aggregate Subscription Amount pursuant to Section 2.1.


 




    	 	1	 



     


    

 


“Closing
Date” means the Business Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchaser’s obligation to pay the Subscription Amount at the Closing, and (ii)
the Company’s obligations to deliver the Securities to be issued and sold at the Closing, in each case, have been satisfied or
waived, but in no event later than the Termination Date unless agreed to by the parties hereto in writing.


 


“Commission”
means the United States Securities and Exchange Commission.


 


“Common
Stock” means the shares of common stock of the Company, par value $0.001 per share, and any other class of securities into
which such securities may hereafter be reclassified or changed.


 


“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.


 


“Company
Counsel” means Anthony L.G., PLLC, United States corporate counsel to the Company.


 


“Convertible
Debenture” means the 15% unsecured convertible debentures issued at par in the aggregate principal amount of $3,000,000.00
pursuant to this Agreement.


 


“Convertible
Debenture Certificate” means the convertible debenture certificate governing the terms of the Convertible Debenture, in the
form attached as Exhibit A hereto.


 


“Conversion
Price” shall have the meaning ascribed to such term in the Convertible Debenture Certificate.


 


“Conversion
Shares” means the Common Stock issued and issuable upon conversion of the Convertible Debenture issued and issuable in lieu
of the cash payment of interest on the Convertible Debenture in accordance with the terms of the Convertible Debenture.


 


“Disclosure
Schedules” means the Disclosure Schedules of the Company delivered concurrently herewith.


 


“Disqualification
Event” shall have the meaning ascribed to such term in Section 3.1 (mm).


 


“Effective
Date” means the earliest of the date that (a) (i) all of the Underlying Shares have been sold pursuant to Rule 144, or (ii)
may be sold by the holders thereof pursuant to Rule 144 without the requirement for the Company to be in compliance with the current
public information required under Rule 144 and without volume or manner-of-sale restrictions, and (b) Company Counsel has delivered to
the Transfer Agent and holders a standing written unqualified opinion that resales may then be made by such holders of the Underlying
Shares pursuant to an effective Registration Statement or the exemption described in (a)(ii) above, which opinion shall be in form and
substance reasonably acceptable to such holders.


 


“Equity
Line of Credit” shall have the meaning ascribed to such term in Section 4.13.


 




    	 	2	 



     


    

 


“Event
of Default” shall have the meaning ascribed thereto in the Convertible Debenture.


 


“Exchange
Act” means the United States Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.


 


“Exempt
Issuance” means the issuance of (a) Common Stock and options to officers, directors, or employees of the Company, prior to
and after the Closing Date up to the amounts and on the terms set forth in their respective option agreements and in accordance with
the rules and policies of the TSX Venture Exchange, (b) securities upon the exercise or exchange of or conversion of any Securities issued
hereunder (subject to adjustment for forward and reverse stock splits and the like that occur after the date hereof) and/or other securities
exercisable or exchangeable for or convertible into Common Stock issued and outstanding on the date of this Agreement, provided that
such securities and any term thereof have not been amended since the date of this Agreement to increase the number of such securities
or to decrease the issue price, exercise price, exchange price or conversion price of such securities, and described in the Public Reports
filed not later than ten (10) days before the Closing Date, (c) securities issued pursuant to acquisitions or strategic transactions
approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a Person (or to
the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business
synergistic with the business of the Company and shall be intended to provide to the Company substantial additional benefits in addition
to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose
of raising capital or to an entity whose primary business is investing in securities, (d) securities issuable pursuant to, and in accordance
with the terms and conditions set forth in the Stock Option Plan as are consistent with past practices and approved by a majority of
the disinterested directors of the Company, not in excess of the amounts permitted by the Stock Option Plan, and (e) securities issued
or issuable pursuant to this Agreement, the Convertible Debenture or the Warrants, or upon exercise or conversion of any such securities.


 


“Exercise
Price” shall have the meaning ascribed to such term in the Warrant Certificate for the Warrants.


 


“FCPA”
means the Foreign Corrupt Practices Act of 1977, as amended.


 


“GAAP”
shall have the meaning ascribed to such term in Section 3.1(h).


 


“G&M”
shall mean Grushko & Mittman, P.C., legal counsel to the Purchasers.


 


“IFRS”
shall have the meaning ascribed to such term in Section 3.1(h).


 


“Indebtedness”
shall have the meaning ascribed to such term in Section 3.1(z).


 


“Intellectual
Property Rights” shall have the meaning ascribed to such term in Section 3.1(o).


 


“Legal
Opinion” shall have the meaning ascribed to such term in Section 2.2(a)(ii).


 


“Legend
Removal Date” shall have the meaning ascribed to such term in Section 4.1(d).


 




    	 	3	 



     


    

 


“Liens”
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, pre-emptive right or other restriction.


 


“Listing
Default” shall have the meaning ascribed to such term in Section 4.11(c).


 


“Majority
in Interest” shall have the meaning ascribed to such term in Section 5.5.


 


“Material
Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b).


 


“Material
Permits” shall have the meaning ascribed to such term in Section 3.1(m).


 


“Maximum
Rate” shall have the meaning ascribed to such term in Section 5.16.


 


“Money
Laundering Laws” shall have the meaning ascribed to such term in Section 3.1(gg).


 


“NI
45-102” means National Instrument 45-102 - Resale of Securities of the Canadian Securities Administrators.


 


“OFAC”
shall have the meaning ascribed to such term in Section 3.1(ii).


 


“Outside
of Canada Purchaser Certificate” means the Outside of Canada Purchaser Certificate attached hereto as Schedule C.


 


“Person”
means an individual or company, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.


 


“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.


 


“Public
Information Failure” shall have the meaning ascribed to such term in Section 4.3(b).


 


“Public
Information Failure Payments” shall have the meaning ascribed to such term in Section 4.3(b).


 


“Purchaser
Party” shall have the meaning ascribed to such term in Section 4.10.


 


“Registration
Rights Agreement” shall mean the registration rights agreement annexed hereto as Exhibit D;


 


“Regulation
S” means Regulation S, as amended, as promulgated under the Securities Act.


 


“Required
Approvals” shall have the meaning ascribed to such term in Section 3.1(e).


 


“Required
Minimum” means, as of any date, the maximum aggregate number of Common Stock then issued or potentially issuable in the future
pursuant to the Transaction Documents, including any Warrant Shares issuable upon exercise in full of all Warrants or Conversion Shares
issuable upon conversion in full of the Convertible Debenture, ignoring any conversion or exercise limits set forth therein, and assuming
that any unconverted portion of the Convertible Debenture will be held until the maturity date of the Convertible Debenture.


 




    	 	4	 



     


    

 


“Securities”
means the Convertible Debenture, Warrants and Underlying Shares.


 


“Securities
Act” means the United States Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.


 


“Securities
Act – British Columbia” means the Securities Act, R.S.B.C. 1996, c. 418, as amended, and the rules and regulations promulgated
thereunder.


 


“Short
Sales” means “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed
to include the location and/or reservation of borrowable Common Stock).


 


“Stock
Option Plan” means the stock option plan referred to in the Company’s Consolidated Financial Statements for the years
ended October 31, 2021 and October 31, 2020 and the Western Magnesium Corporation 2021 Equity Incentive Plan referred to in the Company’s
Notice of Annual and Special Meeting and Management Information Circular dated as of April 20, 2021.


 


“Subscription
Amount” means the aggregate amount to be paid for the Convertible Debenture purchased hereunder on the Closing Date as specified
below the “Name of Purchaser” on the signature pages of this Agreement and next to the heading “Convertible Debenture
principal amount”, in US dollars and in immediately available funds.


 


“Subsidiary”
means with respect to any entity at any date, any direct or indirect Company, limited or general partnership, limited liability company,
trust, estate, association, joint venture or other business entity of which (A) more than 30% of (i) the outstanding capital stock having
(in the absence of contingencies) ordinary voting power to elect a majority of the board of directors or other managing body of such
entity, (ii) in the case of a partnership or limited liability company, the interest in the capital or profits of such partnership or
limited liability company or (iii) in the case of a trust, estate, association, joint venture or other entity, the beneficial interest
in such trust, estate, association or other entity business is, at the time of determination, owned or controlled directly or indirectly
through one or more intermediaries, by such entity, or (B) is under the actual control of the Company.


 


“Termination
Date” shall have the meaning ascribed to such term in Section 2.1.


 


“Trading
Day” means a day on which the principal Trading Market is open for trading.


 


“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the TSX Venture Exchange, NYSE American, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market,
the New York Stock Exchange, the OTC Bulletin Board, the OTCQB, or the OTCQX (or any successors to any of the foregoing). As of the Closing
Date, the TSX Venture Exchange is the Trading Market.


 




    	 	5	 



     


    

  


“Transaction
Documents” means this Agreement, the Convertible Debenture Certificate and the Warrant Certificates, all exhibits and schedules
thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.


 


“Transfer
Agent” means Computershare Investor Services Inc., and any successor transfer agent of the Company.


 


“Underlying
Shares” means the Conversion Shares and the Warrant Shares.


 


“U.S.
Person” means a “U.S. person” as that term is defined in Rule 902(k) of Regulation S;


 


“Unlegended
Shares” shall have the meaning ascribed to such term in Section 4.1(d).


 


“Variable
Priced Equity Linked Instruments” shall have the meaning ascribed to such term in Section 4.13.


 


“Variable
Rate Transaction” shall have the meaning ascribed to such term in Section 4.13.


 


“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the principal Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (Toronto time) to 4:02 p.m. (Toronto time)), (b) if any of the NASDAQ markets or exchanges is not a Trading Market,
the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board, (c) if
the Common Stock is not then listed or quoted for trading on the OTC Bulletin Board and if prices for the Common Stock are then reported
on the OTCQX, OTCQB or OTC Pink Marketplace maintained by the OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the volume weighted average price of the Common Stock on the first such facility (or a similar
organization or agency succeeding to its functions of reporting prices), or (d) in all other cases, the fair market value of a share
of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.


 


“Warrant
Certificate” means the certificate governing the terms of the Warrants, in the form attached as Exhibit B hereto.


 


“Warrant
Shares” means the Common Stock issuable upon exercise of the Warrants.


 


“Warrants”
means, collectively, the Common Stock purchase warrants delivered to the Purchasers upon conversion of the Convertible Debenture in accordance
with the terms of the Convertible Debenture.


 




    	 	6	 



     


    

  


ARTICLE
II.


PURCHASE
AND SALE


 


2.1
Closing. On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the
execution and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers agree to purchase, Convertible
Debentures in the aggregate principal amount of $3,000,000 (the “Closing”). Each Purchaser shall deliver to the Company
its Subscription Amount, and the Company shall deliver to each Purchaser a Convertible Debenture Certificate, and the Company and the
Purchasers shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and
conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of G&M or such other location as the parties
shall mutually agree. Notwithstanding anything herein to the contrary, the Closing Date shall occur on or before April 25, 2022 (the
“Termination Date”). If the Closing is not held on or before the Termination Date, the Company shall cause (i) all
subscription documents executed by the Purchasers to be returned to the Purchasers, and (ii) the Subscription Amount to be returned,
without interest or deduction, to the Purchasers.


 


2.2
Deliveries.


 


(a)
On or prior to the Closing Date, the Company shall deliver or cause to be delivered to the Purchasers the following:


 


(i)
this Agreement duly executed by the Company with the schedules, exhibits or appendices thereto, as applicable, current as of the Closing
Date;




 


(ii)
a legal opinion of Company Counsel acceptable to the Purchasers;


 


(iii)
the Convertible Debenture Certificates to each Purchaser with a principal amount as set forth on the signature pages hereto, registered
in such name as such Purchaser may direct;


 


(iv)
a fully executed Registration Rights Agreement;


 


(v)
a certificate of the Chief Executive Officer (as defined in the Exchange Act) of the Company, dated as of the Closing Date, in which
such officer shall certify that, to the best of his knowledge, the conditions set forth in Section 2.3(b) have been fulfilled;
and


 


(vi)
Officer’s certificate containing (i) copies of the text of the resolutions by which the corporate action on the part of the Company
necessary to approve this Agreement and the other Transaction Documents and the transactions and actions contemplated hereby and thereby,
which shall be accompanied by a certificate of the Chief Financial Officer of Company dated as of the Closing Date certifying to the
Purchasers that such resolutions were duly adopted and have not been amended or rescinded, and (ii) an incumbency certificate dated as
of the Closing Date executed on behalf of Company by its corporate secretary or one of its assistant corporate secretaries certifying
the office of each officer of Company executing this Agreement, or any other agreement, certificate or other instrument executed pursuant
hereto.


 


(b)
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:


 


(i)
this Agreement duly executed by such Purchaser;




 


(ii)
the Registration Rights Agreement duly executed by such Purchaser;


 




    	 	7	 



     


    

 


(iii)
such Purchaser’s Subscription Amount by wire transfer or as otherwise agreed upon by the Parties, to the Company; and


 


(iv)
all documents that such Purchaser is required to execute and deliver under Applicable Laws and the rules and policies of the TSX Venture
Exchange, including the forms set out in Schedules A to D attached hereto, as applicable, to the Company as the issue and sale of the
Securities by the Company to the Purchasers will not be qualified by a prospectus or registration statement.


 


2.3
Closing Conditions.


 


(a)
The obligations of the Company hereunder to effect the Closing are subject to the following conditions being met:


 


(i)
the accuracy in all material respects (determined without regard to any materiality, Material Adverse Effect or other similar qualifiers
therein) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein
in which case they shall be accurate as of such date);


 


(ii)
all obligations, covenants and agreements of the Purchasers required to be performed at or prior to the Closing Date shall have been
performed;


 


(iii)
the delivery by the Purchasers of the items set forth in Section 2.2(b) of this Agreement;


 


(iv)
the issue and sale of the Convertible Debentures being exempt from the requirement to file a prospectus or registration statement and
the requirement to deliver an offering memorandum under Applicable Laws relating to the offer and sale of the Convertible Debentures,
or the Company having received such orders, consents or approvals as may be required to permit such sale without the requirement to file
a prospectus or registration statement or deliver an offering memorandum; and


 


(v)
all necessary regulatory approvals being obtained prior to the Closing Date.


 


(b)
The obligations of the Purchasers hereunder to effect the Closing, unless waived by the Purchasers, are subject to the following conditions
being met:


 


(i)
the accuracy in all material respects (determined without regard to any materiality, Material Adverse Effect or other similar qualifiers
therein) on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein
in which case they shall be accurate as of such date);


 


(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;


 


(iii)
no Event of Default (as defined in the Transaction Documents) shall have occurred under the Transaction Documents;


 


(iv)
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;


 




    	 	8	 



     


    

 


(v)
all necessary regulatory approvals being obtained prior to the Closing Date;


 


(vi)
there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and


 


(vii)
from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the TSX Venture Exchange, and,
at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or
limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on any Trading
Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities, nor shall the Company
have issued any variable rate securities, issued any equity or debt securities at a price lower than the purchase price of the Convertible
Debenture hereunder or conversion price thereof, or have issued any securities with anti dilution features, nor shall there have occurred
any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or
any material adverse change in, any financial market which, in each case, in the reasonable judgment of the Purchasers, makes it impracticable
or inadvisable to purchase the Securities at the Closing.


 


ARTICLE
III.


REPRESENTATIONS
AND WARRANTIES


 


3.1
Representations and Warranties of the Company. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall
be deemed a part hereof and shall qualify any representation made herein to which it refers and any other representation only to the
extent such Disclosure Schedule reasonably relates thereto without a requirement of a cross-reference, the Company hereby makes the following
representations and warranties to the Purchasers as of the date hereof and the Closing Date unless as of a specific date therein in which
case they shall be accurate as of such date:


 


(a)
Subsidiaries. All of the Subsidiaries and the Company’s ownership interests therein are set forth on Schedule 3.1(a).
The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any
Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable
and free of pre-emptive and similar rights to subscribe for or purchase securities. If the Company has no Subsidiaries relevant to any
component of this Agreement as of a relevant time, then such reference shall not be applicable at such time.


 


(b)
Organization and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and capacity to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign Company or other entity in each jurisdiction in which the nature of the business conducted or property owned by
it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not
have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of operations, assets, business, or condition (financial or otherwise) of the
Company and the Subsidiaries, taken as a whole, (iii) a material adverse effect on the Company’s ability to perform in any material
respect on a timely basis its obligations under any Transaction Document, or (iv) the occurrence of a Disqualification Event (any of
(i), (ii), (iii) or (iv), a “Material Adverse Effect”) and, no Proceeding has been instituted in any such jurisdiction
revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.


 




    	 	9	 



     


    

 


(c)
Authorization; Enforcement. The Company has the requisite corporate power and capacity to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no
further action is required by the Company, the Board of Directors or the Company’s stockholders in connection herewith or therewith
other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been
(or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except: (i)
as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by Applicable Law.


 


(d)
No Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents, the
issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby to which it is a party
do not and will not: (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate or articles
of incorporation, bylaws or other organizational or charter documents, (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration, adjustment, exchange,
reset, exercise or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt, equity or other
instrument (evidencing Company or Subsidiary equity, debt or otherwise) or other understanding to which the Company or any Subsidiary
is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) conflict with or result
in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority
to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property
or asset of the Company or a Subsidiary is bound or affected.


 


(e)
Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court, or any federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to Section 4.6 of this Agreement, (ii) the receipt of approval from TSX Venture Exchange; and (iii) the filing of the
required forms with the BCSC, the OTCQB, and the Commission (if any) and such filings as are required to be made under applicable state
securities laws (collectively, the “Required Approvals”).


 




    	 	10	 



     


    

 


(f)
Issuance of the Securities. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and non-assessable, free and clear of all Liens imposed by the Company.
As of the Closing Date, the Company will have reserved its capital stock such number of Common Stock for issuance of the Underlying Shares
at least equal to the Required Minimum on the date hereof.


 


(g)
Capitalization. The capitalization of the Company is as set forth in Schedule 3.1(g). The Company has not issued any Common
Stock since March 17, 2022, other than pursuant to the exercise of employee stock options under the Stock Option Plan, the issuance of
Common Stock to employees pursuant to the Stock Option Plan and pursuant to the conversion and/or exercise of Common Stock Equivalents
outstanding as of the date of the most recently filed periodic report available at EDGAR, or as set forth on Schedule 3.1(g).
No Person has any right of first refusal, pre-emptive right, right of participation, or any similar right to participate in the transactions
contemplated by the Transaction Documents. Except as disclosed on Schedule 3.1(g), there are no outstanding options, employee
or incentive stock option plans, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to,
or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe
for or acquire any Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is
or may become bound to issue additional Common Stock or Common Stock Equivalents. Except as set forth on Schedule 3.1(g), the
issuance and sale of the Securities will not obligate the Company to issue Common Stock or other securities to any Person (other than
the Purchasers) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset
price under any of such securities. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued,
fully paid and non-assessable, have been issued in material compliance with all federal and state securities laws, and none of such outstanding
shares was issued in violation of any pre-emptive rights or similar rights to subscribe for or purchase securities. No further approval
or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There
are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which
the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.


 


(h)
Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required to
be filed by the Company under the Securities Act - British Columbia, the TSX Venture Exchange, the OTCQB, and the Securities Act and
the Exchange Act (if applicable) (collectively, “Public Reports”), for the two years preceding the date hereof (or
such shorter period as the Company was required by law or regulation to file such material) on a timely basis or has received a valid
extension of such time of filing and has filed any such Public Reports prior to the expiration of any such extension. As of their respective
dates, the Public Reports complied in all material respects with the requirements of the Securities Act, the Securities Act - British
Columbia and the Exchange Act, as applicable, and none of the Public Reports, when filed, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading. The financial statements of the Company included in the Public Reports
comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission, BCSC or TSX
Venture Exchange with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance
with international financial reporting standards applied on a consistent basis during the periods involved (“IFRS”)
and in accordance with United States generally accepted accounting principles (“GAAP”), except as may be otherwise
specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes
required by IFRS and GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries
as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited
statements, to normal, immaterial, year-end audit adjustments. The Company is, and has no reason to believe that it will not in the foreseeable
future continue to be in compliance with all its reporting requirements under the Securities Act and Exchange Act.


 




    	 	11	 



     


    

 


(i)
Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included
within the Public Reports, except as specifically disclosed in a subsequent Public Report filed prior to the date hereof or on Schedule
3.1(i): (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material
Adverse Effect, (ii) the Company has not incurred any material liabilities (contingent or otherwise) other than (A) trade payables and
accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected
in the Company’s financial statements pursuant to GAAP or disclosed in public filings made with and available on EDGAR, (iii) the
Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other
property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and
(v) the Company has not issued any equity securities to any officer, director or Affiliate except pursuant to the existing Stock Option
Plan as set forth on Schedule 3.1(i). The Company does not have pending before any Canadian or U.S. regulatory agency or Trading
Market any request for confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement,
or as set forth on Schedule 3.1(i), no event, liability, fact, circumstance, occurrence or development has occurred or exists
or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, properties,
operations, assets or financial condition, that would be required to be disclosed by the Company under Applicable Law at the time this
representation is made or deemed made that has not been publicly disclosed at least two Trading Days prior to the date that this representation
is made.


 


(j)
Litigation. Except as disclosed in Schedule 3.1(j), there is no action, suit, inquiry, notice of violation, proceeding
or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their
respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state,
county, local or foreign) (collectively, an “Action”) which (i) adversely affects or challenges the legality, validity
or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or
reasonably be expected to result in a Material Adverse Effect. Except as set forth in the Public Reports, neither the Company nor any
Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability
under federal or state securities laws or a claim of breach of fiduciary duty. Except as set forth in the Public Reports, there has not
been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by any Canadian or U.S. regulatory
agency or Trading Market involving the Company or any current or former director or officer of the Company. No Canadian or U.S. regulatory
agency or Trading Market issued any stop order or other order suspending the effectiveness of any registration statement filed by the
Company or any Subsidiary.


 




    	 	12	 



     


    

 


(k)
Labor Relations. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or the Subsidiaries’
employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither
the Company nor any of the Subsidiaries is a party to a collective bargaining agreement, and the Company and the Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of the Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and the Subsidiaries are in compliance with all Canadian and U.S. federal,
provincial, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment
and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect.


 


(l)
Compliance. To the Company’s knowledge, neither the Company nor any Subsidiary: (i) is in default under or in violation
of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company
or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is
in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or
any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree
or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance
or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes,
environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each
case as could not have or reasonably be expected to result in a Material Adverse Effect.


 


(m)
Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the Public Reports,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (“Material
Permits”), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.


 


(n)
Title to Assets. The Company and the Subsidiaries have good and marketable title in fee simple to all real property (if any) owned
by them and good and marketable title in all personal property (including domain names) owned by them that is material to the business
of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value
of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries
and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made in accordance with IFRS
and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company
and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are
in compliance.


 




    	 	13	 



     


    

 


(o)
Intellectual Property. All of the Company’s and Subsidiary’s Intellectual Property Rights are described in the Public
Reports.


 


(i)
The term “Intellectual Property Rights” means:


 


	 	1.	the
    name of the Company and each Subsidiary, all fictional business names, trading names, registered and unregistered trademarks, service
    marks, and applications of the Company and each Subsidiary (collectively, “Marks”);
	 	 	 
	 	2.	all
    patents and patent applications of the Company and each Subsidiary (collectively, “Patents”);
	 	 	 
	 	3.	all
    copyrights in both published works and unpublished works of the Company and each Subsidiary (collectively, “Copyrights”);
    and
	 	 	 
	 	4.	all
    know-how, trade secrets, confidential information, customer lists, software, technical information, data, process technology, plans,
    drawings, and blue prints (collectively, “Trade Secrets”); owned, used, or licensed by the Company and each Subsidiary
    as licensee or licensor.


 


(ii)
Agreements. There are no outstanding and, to Company’s knowledge, no threatened disputes or disagreements with respect to
any agreements relating to any Intellectual Property Rights to which the Company is a party or by which the Company is bound.


 


(iii)
Know-How Necessary for the Business. The Intellectual Property Rights are all those necessary for the operation of the Company’s
businesses as it is currently conducted or as represented, in writing, to the Purchasers to be conducted. The Company is the owner of
all right, title, and interest in and to each of the Intellectual Property Rights, free and clear of all Liens, and adverse claims, and
has the right to use all of the Intellectual Property Rights. To the Company’s knowledge, no employee of the Company has entered
into any contract that restricts or limits in any way the scope or type of work in which the employee may be engaged or requires the
employee to transfer, assign, or disclose information concerning his work to anyone other than of the Company.


 


(iv)
Patents. The Company owns no Patents and has no patents pending. The Company and the Subsidiaries have, or have rights to use,
all Patents necessary or required for use in connection with their respective businesses as described in the Public Reports and which
the failure to so have could have a Material Adverse Effect (collectively, the “Intellectual Property Rights”). None
of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Patents has expired, terminated
or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement. Neither
the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the Public Reports,
a written notice of a claim or otherwise has any knowledge that the Patents violate or infringe upon the rights of any Person, except
as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Patents
are enforceable and there is no existing infringement by another Person of any of the Patents. The Company and the Subsidiaries have
taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except
where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.


 




    	 	14	 



     


    

 


(v)
Trademarks. The Company is the owner of all right, title, and interest in and to each of the Marks, free and clear of all Liens
and other adverse claims. All Marks that have been registered with the United States Patent and Trademark Office are currently in compliance
with all formal legal requirements (including the timely post-registration filing of affidavits of use and incontestability and renewal
applications), are valid and enforceable, and are not subject to any maintenance fees or taxes or actions falling due within ninety days
after the Closing Date. No Mark has been or is now involved in any opposition, invalidation, or cancellation and, to the Company’s
knowledge, no such action is threatened with respect to any of the Marks. To the Company’s knowledge: (1) there is no potentially
interfering trademark or trademark application of any third party, and (2) no Mark is infringed or has been challenged or threatened
in any way. To the Company’s knowledge, none of the Marks used by the Company infringes or is alleged to infringe any trade name,
trademark, or service mark of any third party.


 


(vi)
Copyrights. The Company is the owner of all right, title, and interest in and to each of the Copyrights, free and clear of all
Liens and other adverse claims. All the Copyrights have been registered and are currently in compliance with formal requirements, are
valid and enforceable, and are not subject to any maintenance fees or taxes or actions falling due within ninety days after the date
of the Closing. No Copyright is infringed or, to the Company’s knowledge, has been challenged or threatened in any way. To the
Company’s knowledge, none of the subject matter of any of the Copyrights infringes or is alleged to infringe any copyright of any
third party or is a derivative work based on the work of a third party. All works encompassed by the Copyrights have been marked with
the proper copyright notice.


 


(vii)
Trade Secrets. With respect to each Trade Secret, the documentation relating to such Trade Secret is current, accurate, and sufficient
in detail and content to identify and explain it and to allow its full and proper use without reliance on the knowledge or memory of
any individual. The Company has taken all reasonable precautions to protect the secrecy, confidentiality, and value of its Trade Secrets.
The Company has good title and an absolute (but not necessarily exclusive) right to use the Trade Secrets. The Trade Secrets are not
part of the public knowledge or literature, and, to the Company’s knowledge, have not been used, divulged, or appropriated either
for the benefit of any Person (other the Company) or to the detriment of the Company. No Trade Secret is subject to any adverse claim
or has been challenged or threatened in any way.


 


(p)
Insurance. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged. Neither
the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant
increase in cost.


 




    	 	15	 



     


    

 


(q)
Transactions With Affiliates and Employees. Except as set forth in the Public Reports, none of the officers or directors of the
Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a
party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any
officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee
has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $50,000 other
than for: (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company
or any Subsidiary, and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company except
as disclosed in the Public Reports.


 


(r)
Compliance; Internal Accounting Controls. The Company is in material compliance with any and all applicable requirements of Securities
Laws and filing and disclosure obligations with the principal Trading Market that are effective as of the date hereof, and as of the
Closing Date. The Company maintains a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions
are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with IFRS and GAAP and to maintain asset accountability, and (iii) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences.


 


(s)
Certain Fees. No brokerage, finder’s fees, commissions or due diligence fees are or will be payable by the Company or any
Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect
to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any such fees
or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section 3.1(s) that may be
due in connection with the transactions contemplated by the Transaction Documents.


 


(t)
Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an “investment company” subject to registration
under the Investment Company Act of 1940, as amended.


 


(u)
Registration Rights. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities
Act of any securities of the Company or any Subsidiary, except for the Purchasers and as set forth in the Public Reports.


 


(v)
Reporting Company/Shell Company. The Company has no reason to believe that it will not in the year following the Closing Date
continue to be in compliance with all listing and reporting requirements applicable to the Company as of the Closing Date. As of the
Closing Date, the Company is not a “shell company” (as defined in Rule 405 of the Securities Act) and has never been a “shell
company”.


 




    	 	16	 



     


    

 


(w)
Application of Takeover Protections. The Company and the Board of Directors will have taken as of the Closing Date all necessary
action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or other similar anti-takeover provision under the Company’s certificate of incorporation (or similar
charter documents) and the laws of the British Columbia that are or could become applicable to the Purchasers as a result of the Purchasers
and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation
as a result of the Company’s issuance of the Securities and the Purchasers’ ownership of the Securities.


 


(x)
Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company confirms that neither it nor any other Person acting on its behalf has provided the Purchasers or their agents or counsel
with any information that it believes constitutes or might constitute material, non-public information. The Company understands and confirms
that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure
furnished by or on behalf of the Company to the Purchasers regarding the Company and the Subsidiaries, their respective businesses and
the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, when taken together as a whole, is true and
correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements made therein, in light of the circumstances under which they were made, not misleading. The press releases disseminated by
the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of
the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes
or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set
forth in Section 3.2 hereof.


 


(y)
No Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause the Offering of the Securities
to be integrated with prior offerings by the Company for purposes of: (i) the Securities Act which would require the registration of
any such securities under the Securities Act, (ii) any applicable shareholder approval provisions of any Trading Market on which any
of the securities of the Company are listed or designated, or (iii) any other Applicable Law. Neither the Company nor any Subsidiary
is in default with respect to any Indebtedness.


 




    	 	17	 



     


    

 


(z)
Solvency. Based on the consolidated financial condition of the Company as of the Closing Date, and the Company’s good faith
estimate of the fair market value of its assets, after giving effect to the receipt by the Company of the proceeds from the sale of the
Securities hereunder: (i) the fair saleable value of the Company’s assets exceeds the amount that will be required to be paid on
or in respect of the Company’s existing debts and other liabilities (including known contingent liabilities) as they mature, (ii)
the Company’s assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to
be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the Company,
consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the Company, together
with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of
the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company
does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash
to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that
it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the
Closing Date. Schedule 3.1(z) sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company
or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, “Indebtedness”
means (x) any liabilities for borrowed money, (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness
of others, whether or not the same are or should be reflected in the Company’s consolidated balance sheet (or the notes thereto),
except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of
business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance
with IFRS and GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.


 


(aa)
Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and the Subsidiaries each (i) has made or filed all United States and Canadian federal, provincial,
state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which
it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined
to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment
of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid
taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any
Subsidiary know of no basis for any such claim.


 


(bb)
Foreign Corrupt Practices. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any
agent or other person acting on behalf of the Company or any Subsidiary, has: (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law or (iv) violated in any material respect any provision of FCPA.


 


(cc)
Accountants and Lawyers. The Company’s audit firm is disclosed in the Public Records. To the knowledge and belief of the
Company, such accounting firm is a participating audit firm with the Canadian Public Accountability Board. There are no disagreements
of any kind presently existing, or reasonably anticipated by the Company to arise, between the Company and the accountants and lawyers
formerly or presently employed by the Company and the Company is current with respect to any fees owed to its accountants and lawyers
which could affect the Company’s ability to perform any of its obligations under any of the Transaction Documents.


 




    	 	18	 



     


    

 


(dd)
Acknowledgment Regarding Purchasers’ Purchase of Securities. The Company acknowledges and agrees that the Purchasers are
acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that the Purchasers are not acting as a financial advisor or fiduciary of the Company (or in
any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by the
Purchasers or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated
thereby is merely incidental to the Purchasers’ purchase of the Securities. The Company further represents to the Purchasers that
the Company’s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent
evaluation of the transactions contemplated hereby by the Company and its representatives.


 


(ee)
Acknowledgment Regarding Purchasers’ Trading Activity. Anything in this Agreement or elsewhere
herein to the contrary notwithstanding, it is understood and acknowledged by the Company that: (i) the Purchasers have not been asked
by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company,
or “derivative” securities based on securities issued by the Company or to hold the Securities for any specified term, (ii)
past or future open market or other transactions by a Purchaser, specifically including, without limitation, Short Sales or “derivative”
transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of
the Company’s publicly-traded securities, (iii) a Purchaser, and counter-parties in “derivative” transactions to which
a Purchaser is a party, directly or indirectly, may presently have a “short” position in the Common Stock and
(iv) a Purchaser shall not be deemed to have any affiliation with or control over any arm’s length counter-party in any “derivative”
transaction. The Company further understands and acknowledges that (y) a Purchaser may engage in hedging activities at various
times during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the
Underlying Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce
the value of the existing stockholders’ equity interests in the Company at and after the time that the hedging activities are being
conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction
Documents.


 


(ff)
Regulation M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any
of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company.


 


(gg)
Money Laundering. The operations of the Company and the Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the U.S. Currency and Foreign Transactions Reporting Act of 1970, as
amended, and the Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada), as amended, applicable money laundering
statutes and applicable rules and regulations thereunder (collectively, the “Money Laundering Laws”), and no action,
suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary
with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.


 




    	 	19	 



     


    

 


(hh)
Stock Option Plan. To the knowledge of the Company, other than as disclosed in the Public Filings, each stock option granted by
the Company under the Stock Option Plan was granted (i) in accordance with the terms of such Stock Option Plan and (ii) with an exercise
price at least equal to the fair market value of the Common Stock on the date such stock option would be considered granted under IFRS,
GAAP and Applicable Law. No stock option granted under the Stock Option Plan has been backdated. The Company has not knowingly granted,
and there is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate
the grant of stock options with, the release or other public announcement of material information regarding the Company or the Subsidiaries
or their financial results or prospects.


 


(ii)
Office of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director,
officer, agent, employee or affiliate of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department (“OFAC”).


 


(jj)
Private Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2, no
registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated
hereby. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Trading Market.


 


(kk)
No General Solicitation. Neither the Company nor any person acting on behalf of the Company has offered or sold any of the Securities
by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Purchasers and
certain other “accredited investors” within the meaning of Rule 501 under the Securities Act.


 


(ll)
Indebtedness and Seniority. As of the date hereof, all Indebtedness and Liens of the Company and the principal terms thereof are
set forth on Schedule 3.1(ll). Except as set forth on Schedule 3.1(ll), as of the Closing Date, no Indebtedness or other
equity of the Company is or will be senior to the Convertible Debenture in right of payment, whether with respect to interest or upon
liquidation or dissolution, or otherwise, other than indebtedness secured by purchase money security interests (which is senior only
as to underlying assets covered thereby) and capital lease obligations (which is senior only as to the property covered thereby).


 


(mm)
No Disqualification Events. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under the
Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of
the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company’s outstanding voting equity
securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act)
connected with the Company in any capacity at the time of sale (each, an “Issuer Covered Person” and, together, “Issuer
Covered Persons”) is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii)
under the Securities Act (a “Disqualification Event”), except for a Disqualification Event covered by Rule 506(d)(2)
or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification
Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the
Purchasers a copy of any disclosures provided thereunder.


 




    	 	20	 



     


    

 


(nn)
Manufacturing Regulatory Matters. The Company and the Subsidiaries have complied in all material respects with all statutes and
regulations related to the research, manufacture and sale of its products to the extent applicable to the Company’s and the Subsidiaries’
activities. Items manufactured or under investigation by the Company and the Subsidiaries comply with all applicable manufacturing practices
regulations and other requirements established by government regulators in the jurisdictions in which the Company or the Subsidiaries
manufacture their products. Except as disclosed in the Public Reports, the Company is not and the Subsidiaries are not the subject of
any investigation by any competent authority with respect to the development, testing, manufacturing and distribution of their products,
nor has any investigation, prosecution, or other enforcement action been threatened by any regulatory agency. Except as disclosed in
the Public Reports, neither the Company nor any of the Subsidiaries has received from any regulatory agency any letter or other document
asserting that the Company or any Subsidiary has violated any statute or regulation enforced by that agency with respect to the development,
testing, manufacturing and distribution of their products. To the Company’s knowledge, research conducted by or for the Company
and the Subsidiaries has complied in all material respects with all applicable legal requirements.


 


(oo)
Other Covered Persons. The Company is not aware of any person that has been or will be paid (directly or indirectly) remuneration
for solicitation of purchasers in connection with the sale of any Regulation D Securities.


 


(pp)
No Outstanding Variable Priced Equity Linked Instruments. As of the Closing Date, the Company will not have outstanding nor issuable
any Variable Priced Equity Linked Instruments, nor any debt or equity with anti-dilution, ratchet or reset rights.


 


(qq)
Listing and Maintenance Requirements. The Common Stock is listed on the TSX Venture Exchange under the symbol WMG.V and on the
OTCQB under the symbol MLYF. The Company has not received notice from any Trading Market on which the Common Stock is or has been listed
or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market.


 


(rr)
Environmental and Safety Laws.


 


(i)
The Company is, and at all times has been, in full compliance with, and has not been and is not in violation of or liable under, any
Environmental Law. The Company has no basis to expect, nor has it or any other Person for whose conduct it is or may be held to be responsible
received, any actual or threatened order, notice, or other communication from (i) any governmental body or private citizen acting in
the public interest, or (ii) the current or prior owner or operator of any facilities, of any actual or potential violation or failure
to comply with any Environmental Law, or of any actual or threatened obligation to undertake or bear the cost of any environmental, health,
and safety liabilities with respect to any of the facilities or any other properties or assets (whether real, personal, or mixed) in
which the Company has had an interest, or with respect to any property or facility at or to which Hazardous Materials were generated,
manufactured, refined, transferred, imported, used, or processed by the Company, or any other Person for whose conduct it is or may be
held responsible, or from which Hazardous Materials have been transported, treated, stored, handled, transferred, disposed, recycled,
or received.


 


(ii)
There are no pending or, to the knowledge of the Company, threatened claims, encumbrances, or other restrictions of any nature, resulting
from any environmental, health, and safety liabilities or arising under or pursuant to any Environmental Law, with respect to or affecting
any of the facilities or any other properties and assets (whether real, personal, or mixed) in which the Company has or had an interest.


 




    	 	21	 



     


    

 


 


(iii)
The Company has no knowledge of any basis to expect, nor has it or any other Person for whose conduct it is or may be held responsible,
received, any citation, directive, inquiry, notice, order, summons, warning, or other communication that relates to Hazardous Materials,
or any alleged or actual violation or failure to comply with any Environmental Law, or of any alleged or actual obligation to undertake
or bear the cost of any environmental, health, and safety liabilities with respect to any of the facilities or any other properties or
assets (whether real, personal, or mixed) in which the Company had an interest, or with respect to any property or facility to which
Hazardous Materials generated, manufactured, refined, transferred, imported, used, or processed by the Company, or any other Person for
whose conduct it is or may be held responsible, have been transported, treated, stored, handled, transferred, disposed, recycled, or
received.


 


(iv)
Neither the Company nor any other Person for whose conduct it is or may be held responsible, had any environmental, health, and safety
liabilities with respect to the facilities or, to the knowledge of the Company, with respect to any other properties and assets (whether
real, personal, or mixed) in which the Company (or any predecessor), has or had an interest, or at any property geologically or hydrologically
adjoining the facilities or any such other property or assets.


 


(v)
Neither the Company nor any other Person for whose conduct it is or may be held responsible, or to the knowledge of the Company, any
other Person, has permitted or conducted, or is aware of, any hazardous activity conducted with respect to the facilities or any other
properties or assets (whether real, personal, or mixed) in which the Company has or had an interest except in full compliance with all
applicable Environmental Laws.


 


(vi)
There has been no release of any Hazardous Materials at or from the facilities or at any other locations where any Hazardous Materials
were generated, manufactured, refined, transferred, produced, imported, used, or processed from or by the facilities, or from or by any
other properties and assets (whether real, personal, or mixed) in which the Company has or had an interest, or to the knowledge of the
Company any geologically or hydrologically adjoining property, whether by the Company, or any other Person that has had a Material Adverse
Effect.


 


(vii)
For the purpose of this Section, Hazardous Material shall mean (i) materials which are listed or otherwise defined as “hazardous”
or “toxic” under any applicable federal, local or stated and/or foreign laws and regulations that govern the existence and/or
remedy of contamination on property, the protection of the environment from contamination, the control of the hazardous wastes, or other
activities involving hazardous substances, including building materials or (b) petroleum products or nuclear materials.


 


(viii)
For the purpose of this Section 3.1(rr), “Environmental Law” shall have the following meaning:


 


(1)
advising appropriate authorities, employees, and the public intended or actual releases of pollutants or hazardous substances or material,
violations of discharge limits, or other prohibitions and of the commencements of activities, such as resource extraction or construction,
that could have significant impact on the environment;


 


(2)
preventing or reducing to acceptable levels the release of pollutants or hazardous substances or materials into the environment;


 




    	 	22	 



     


    

 


(3)
reducing the quantities, preventing the release, or minimizing the hazardous characteristics of waste that are generated;


 


(4)
assuring that products are designed, formulated, packaged, and used so that they do not present unreasonable risks to human health or
the environment when used or disposed of;


 


(5)
protecting resources, species or ecological amenities;


 


(6)
reducing to acceptable levels the risk inherent in the transportation of hazardous substances, pollutants, oil or other potentially harmful
substances;


 


(7)
cleaning up pollutants that have been released, preventing the threat of release or paying the costs of such clean up or prevention;
or


 


(8)
making responsible parties pay private parties, or groups of them, for damages done to their health or to the environment, or permitting
self-appointed representatives of the public interest to recover for injuries done to public assets.


 


(ss)
Survival. The foregoing representations and warranties shall survive the Closing and continue in full force and effect for the
benefit of the Purchasers for a period of six years following the Closing.


 


3.2
Representations and Warranties of the Purchasers. Each Purchaser, for itself and for no other Purchaser, hereby represents and
warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein):


 


(a)
Organization; Authority. Such Purchaser, if an individual, is of the full age of majority in his or her jurisdiction of residence
and is legally competent to execute, deliver and be bound by the terms of this Agreement, to subscribe for the Convertible Debenture
contemplated herein and to observe and perform his or her covenants and obligations hereunder, OR if an entity, is duly incorporated
or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right,
corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated
by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction
Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by
all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each
Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance
with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance
with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to
the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by Applicable Law.


 




    	 	23	 



     


    

 


(b)
Understandings or Arrangements. Such Purchaser understands that the Securities are “restricted securities” and have
not been registered under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for
its own account, not for the benefit of any other Person (within the meaning of Applicable Laws) and not with a view to or for distributing
or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present
intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities law and has no
direct or indirect arrangement or understandings with any other persons to act jointly or in concert in connection with the Offering
to distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities
law (this representation and warranty not limiting such Purchaser’s right to sell the Securities pursuant to any registration statement
or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in
the ordinary course of its business.


 


(c)
Purchaser Status. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each
date on which it exercises any Warrants or converts the Convertible Debenture it will be either: (i) an “accredited investor”
as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act or (ii) a “qualified institutional buyer”
as defined in Rule 144A(a) under the Securities Act. Such Purchaser is able to bear the risk of such investment for an indefinite period
and to afford a complete loss thereof. Such Purchaser has provided the information in the Accredited Investor Questionnaire attached
hereto as Schedule C (the “Investor Questionnaire”). The information set forth on the signature pages hereto
and the Investor Questionnaire regarding such Purchaser is true and complete in all respects. Except as disclosed in the Investor Questionnaire,
such Purchaser has had no position, office or other material relationship within the past three years with the Company or Persons (as
defined below) known to such Purchaser to be affiliates of the Company, and is not a member of the Financial Industry Regulatory Authority
or an “associated person” (as such term is defined under the FINRA Membership and Registration Rules Section 1011).


 


(d)
Canadian Private Placement Provision. Such Purchaser’s ability to transfer the Convertible Debenture, Warrants and Underlying
Shares is limited by, among other things, the United States and Canadian securities laws and the policies of the TSX Venture Exchange.
In particular, such Purchaser acknowledges having been informed that the Convertible Debenture and Warrants, and any Underlying Shares
issued upon exercise of the Warrants or conversion of the Convertible Debenture, are subject to resale restrictions under NI 45-102 and
may not be sold or otherwise disposed of in Canada for a period of four months from the date of distribution of the Convertible Debenture,
unless a statutory exemption is available or a discretionary order is obtained from the BCSC allowing the earlier resale thereof, and
may be subject to additional resale restrictions if such sale or other disposition would be a “control distribution”, as
that term is defined in NI 45-102. If such Purchaser is not resident in Canada, additional resale restrictions may apply under other
Applicable Law. In addition, the policies of the TSX Venture Exchange may require that the Shares, Warrants and any Underlying Shares
issued upon exercise of the Warrants or upon conversion of the Convertible Debenture, not be sold or otherwise disposed of for a period
of not less than four months from the Closing Date. Such Purchaser is resident or, if not an individual, has its head office, in the
jurisdiction set out on such Purchaser signature page of this Agreement. Such address was not created and is not used solely for the
purpose of acquiring the Convertible Debenture. Such Purchaser has completed and delivered the Outside of Canada Purchaser Certificate
attached as Schedule C hereto, makes the representations, warranties and covenants therein and confirms the truth and accuracy of all
statements in such schedule as of the date of this Agreement and as of the Closing Date.


 




    	 	24	 



     


    

 


(e)
Experience of the Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, is aware of the characteristics of the Convertible Debenture and Warrants and has so evaluated and understands the
merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the
present time, is able to afford a complete loss of such investment.


 


(f)
Information on Company. Such Purchaser has been furnished with or has had access to the SEDAR and EDGAR website to the Company’s
filings made with the applicable Canadian or U.S. regulatory agency or Trading Market through the tenth business day preceding the Closing
Date in which such Purchaser purchases Securities hereunder. Such Purchaser is not deemed to have any knowledge of any information not
included in the Public Reports unless such information is delivered in the manner described in the next sentence. In addition, such Purchaser
may have received in writing from the Company such other information concerning its operations, financial condition and other matters
as such Purchaser has requested, identified thereon as OTHER WRITTEN INFORMATION (such other information is collectively, the “Other
Written Information”), and considered all factors such Purchaser deems material in deciding on the advisability of investing
in the Securities. Such Purchaser was afforded (i) the opportunity to ask such questions as such Purchaser deemed necessary of, and to
receive answers from, representatives of the Company concerning the merits and risks of acquiring the Securities; (ii) the right of access
to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient
to enable such Purchaser to evaluate the Securities; and (iii) the opportunity to obtain such additional information that the Company
possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect
to acquiring the Securities.


 


(g)
Communication of Offer. Such Purchaser is not purchasing the Securities as a result of any “general solicitation”
or “general advertising,” as such terms are defined in Regulation D, which includes, but is not limited to, any advertisement,
article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or on the internet
or broadcast over television, radio or the internet or presented at any seminar or any other general solicitation or general advertisement.


 


(h)
No Governmental Review. Such Purchaser understands that no United States federal or state agency or any other governmental or
state agency has passed on or made recommendations or endorsement of the Securities or the suitability of the investment in the Securities
nor have such authorities passed upon or endorsed the merits of the Offering.


 


(i)
No Conflicts. The execution, delivery and performance of this Agreement and performance under the other Transaction Documents
and the consummation by such Purchaser of the transactions contemplated hereby and thereby or relating hereto or thereto do not and will
not (i) result in a violation of such Purchaser’s charter documents, bylaws or other organizational documents, if applicable, (ii)
conflict with nor constitute a default (or an event which with notice or lapse of time or both would become a default) under any agreement
to which such Purchaser is a party, nor (iii) result in a violation of any law, rule, or regulation, or any order, judgment or decree
of any court or governmental agency applicable to such Purchaser or its properties (except for such conflicts, defaults and violations
as would not, individually or in the aggregate, have a material adverse effect on such Purchaser). Such Purchaser is not required to
obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency in order for
it to execute, deliver or perform any of its obligations under this Agreement or perform under the other Transaction Documents nor to
purchase the Securities in accordance with the terms hereof, provided that for purposes of the representation made in this sentence,
such Purchaser is assuming and relying upon the accuracy of the relevant representations and agreements of the Company herein.


 




    	 	25	 



     


    

 


(j)
Pre-Existing Relationships. Such Purchaser represents and warrants that: (i) such Purchaser is not investing in the Offering in
connection with or as a result of any registration statement filed with any Canadian or U.S. regulatory agency or Trading Market by the
Company and (ii) no Securities were offered or sold to it by means of any form of general solicitation or general advertising, and in
connection therewith, such Purchaser did not (A) receive or review any advertisement, article, notice or other communication published
in a newspaper or magazine or similar media or broadcast over television or radio, whether closed circuit, or generally available; or
(B) attend any seminar meeting or industry investor conference whose attendees were invited by any general solicitation or general advertising;
or (C) observe any website or filing of the Company with any U.S. or Canadian regulatory agency or Trading Market in which any offering
of securities by the Company was described and as a result learned of any offering of securities by the Company.


 


(k)
Prospectus Exemptions. The issue and sale of the Securities by the Company to such Purchaser is conditional upon such sale being
exempt from the requirements as to the filing of a prospectus or registration statement and as to the preparation of an offering memorandum
or similar document contained in any statute, regulation, instrument, rule or policy applicable to the sale of the Securities or upon
the issue of such orders, consents or approvals as may be required to permit such sale without the requirement of filing a prospectus
or registration statement or delivering an offering memorandum or similar document.


 


Such
Purchaser acknowledges and agrees that:


 


(i)
it has been independently advised as to or are aware of the restrictions with respect to trading in, and the restricted period or statutory
hold period applicable to, the Securities imposed by the Securities Laws of the jurisdiction in which it resides or to which it is subject
and by the policies of the TSX Venture Exchange, that a suitable legend or legends will be placed on the certificates representing the
Convertible Debenture and Warrants and, if necessary, the Conversion Shares underlying the Convertible Debenture and Warrants to reflect
the applicable restricted period and statutory hold period to which the Convertible Debenture and Warrants and, if applicable, the Underlying
Shares are subject;


 


(ii)
it has not received or been provided with a prospectus, registration statement, offering memorandum (within the meaning of the Applicable
Law) or any document purporting to describe the business and affairs of the Company which has been prepared for review by prospective
purchasers to assist in making an investment decision in respect of the Securities; and that its decision to enter into this Agreement
and to purchase the Securities from the Company is based entirely upon publicly available information concerning the Company (other than
the representations and warranties made by the Company in this Agreement), and not upon any other verbal or written representation as
to fact or otherwise made by or on behalf of the Company;


 


(iii)
there are risks associated with the purchase of the Securities, including, but not limited to, the risk factors described in the Public
Reports and such Purchaser may lose its entire investment;


 


(iv)
it acknowledges that it has had such opportunity as it has deemed adequate to conduct all due diligence investigations regarding the
business, financial position, condition and prospects of the Company as is necessary to permit it to evaluate the merits and risks of
its investment in the Securities;


 




    	 	26	 



     


    

 


(v)
such Purchaser is solely responsible for obtaining such tax, investment, legal and other professional advice as it considers appropriate
in connection with the execution, delivery and performance by it of this Agreement and the transactions contemplated hereunder (including
the resale and transfer restrictions referred to herein), and, without limiting the generality of the foregoing, the Company’s
counsel is acting solely as counsel to the Company and not as counsel to such Purchaser;


 


(vi)
as a consequence of the sale being exempt from the prospectus requirements of the Applicable Law:


 


(1)
certain protections, rights and remedies provided by the Applicable Law, including statutory rights of rescission and certain statutory
remedies against an issuer, underwriters, auditors, directors and officers that are available to investors who acquire securities offered
by a prospectus, will not be available to it;


 


(2)
the common law may not provide investors with an adequate remedy in the event that they suffer investment losses in connection with securities
acquired in a private placement;


 


(3)
it may not receive information that would otherwise be required to be given under the Applicable Law; and


 


(4)
there is no government or other insurance covering the Securities;


 


(vii)
no Person has made any written or oral representation to it:


 


(1)
that any Person will resell or repurchase the Convertible Debenture, Warrants or Underlying Shares; or


 


(2)
as to the future price or value of the Underlying Shares; and


 


(l)
Such Purchaser has not become aware of any advertisement in printed media of general and regular paid circulation (or other printed public
media), radio, television or telecommunications, or other form of advertisement (including the electronic display such as the Internet)
with respect to the distribution of the Convertible Debenture and Warrants.


 


(m)
The funds representing the such Purchaser’s portion of the Purchase Price in respect of the Securities which will be advanced by
such Purchaser to the Company hereunder will not represent proceeds of crime for the purposes of the Proceeds of Crime (Money Laundering)
and Terrorist Financing Act (Canada) (for the purposes of this paragraph the “PCMLTFA”) and it acknowledges that
the Company may in the future be required by law to disclose the name of such Purchaser and other information relating to this Agreement
and the subscription hereunder, on a confidential basis, pursuant to the PCMLTFA. To the best of such Purchaser’s knowledge (a)
none of the subscription funds provided by such Purchaser (i) have been or will be derived directly or indirectly from or related to
any activity that is deemed criminal under the laws of Canada, the United States of America, or any other jurisdiction, or (ii) are being
tendered on behalf of a person or entity who has not been identified by such Purchaser and, (b) such Purchaser will promptly notify the
Company if it discovers that any of such representations cease to be true, and to provide the Company with appropriate information in
connection therewith.


 




    	 	27	 



     


    

 


(n)
Such Purchaser on its own behalf and, if applicable, on behalf of each beneficial purchaser for whom it is contracting hereunder, acknowledge
and consent to the fact that the Company is collecting its personal information (as that term is defined under applicable privacy legislation,
including, without limitation, the Personal Information Protection and Electronic Documents Act (Canada) and any other applicable
similar, replacement or supplemental provincial or federal legislation or laws in effect from time to time), and, if applicable, that
of each beneficial purchaser for whom it is contracting hereunder, for the purpose of completing this Agreement. Such Purchaser on its
own behalf and, if applicable, on behalf of each beneficial purchaser for whom it is contracting hereunder, acknowledge and consent to
the Company retaining such personal information for as long as permitted or required by law or business practices. Such Purchaser, on
its own behalf and, if applicable, on behalf of each beneficial purchaser for whom it is contracting hereunder, further acknowledge and
consent to the fact that the Company may be required by applicable Securities Laws, the rules and policies of any stock exchange or the
rules of the Investment Industry Regulatory Organization of Canada to provide regulatory authorities with any personal information provided
under this Agreement. Such Purchaser represents and warrants, as applicable, that it has the authority to provide the consents and acknowledgements
set out in this paragraph on behalf of each beneficial purchaser for whom it is contracting hereunder. In addition to the foregoing,
such Purchaser agrees and acknowledges that the Company, as the case may be, may use and disclose such Purchaser’s personal information,
or that of each beneficial purchaser for whom it is contracting hereunder, as follows:


 


	 	(i)	for
    internal use with respect to managing the relationships between and contractual obligations of the Company, and such Purchaser or
    any beneficial purchaser for whom it is contracting hereunder;
	 	 	 
	 	(ii)	for
    use and disclosure for income tax related purposes, including, without limitation, where required by law, disclosure to Canada Revenue
    Agency;
	 	 	 
	 	(iii)	for
    disclosure to stock exchanges and securities regulatory authorities and other regulatory bodies with jurisdiction with respect to
    approval or acceptance for filing of the Offering, reports of trades and similar stock exchange or regulatory filings including,
    without limiting the generality of the foregoing, disclosure to the TSX Venture Exchange pursuant to the Form 4B Private Placement
    Notice Form to be filed by the Company in respect of the Offering and the collection, use and disclosure thereof by the TSX Venture
    Exchange for the purposes described in Exhibit I or as otherwise identified by the TSX Venture Exchange from time to time;
	 	 	 
	 	(iv)	for
    disclosure to a governmental or other authority to which the disclosure is required by court order or subpoena compelling such disclosure
    and where there is no reasonable alternative to such disclosure;
	 	 	 
	 	(v)	for
    disclosure to professional advisers of the Company in connection with the performance of their professional services;


 




    	 	28	 



     


    

 


	 	(vi)	for
    disclosure to any person where such disclosure is necessary for legitimate business reasons and is made with such Purchaser prior
    written consent;
	 	 	 
	 	(vii)	for
    disclosure to a court determining the rights of the parties under this Agreement; or
	 	 	 
	 	(viii)	for
    use and disclosure as otherwise required or permitted by law; and


 


(o)
Survival. The foregoing representations and warranties shall survive the Closing and continue in full force and effect for the
benefit of the Company for a period of six years following the Closing.


 


The
Company acknowledges and agrees that the representations contained in Section 3.2 shall not modify, amend or affect the Purchasers’
right to rely on the Company’s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transaction contemplated hereby.


 


ARTICLE
IV.


OTHER
AGREEMENTS OF THE PARTIES


 


4.1
Transfer Restrictions.


 


(a)
Disposition of Securities. The Securities may only be disposed of in compliance with provincial, state and federal securities
laws in Canada or the United States, as the case may be. In connection with any transfer of Securities (other than pursuant to an effective
registration statement or NI 45-102, or to an Affiliate of such Purchaser or in connection with a pledge as contemplated in Section 4.1(b)),
the Company may require the transferor thereof to provide to the Company, at the Company’s expense, an opinion of counsel selected
by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory
to the Company, to the effect that such transfer does not require registration of such transferred Securities under the Securities Act.
As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and shall have the
rights and obligations of such Purchaser under this Agreement and the other Transaction Documents.


 




    	 	29	 



     


    

 


(b)
Legend.


 


(i)
Canadian Provisions. Each Purchaser acknowledges that a legend will be endorsed on the certificates representing the Convertible
Debenture and, if any Warrants are exercised or if the Convertible Debenture is converted prior to the expiry of the statutory or any
applicable TSX Venture Exchange imposed resale restrictions, a legend will be endorsed on the certificates representing the Warrants
and the Underlying Shares, to the effect that the securities represented thereby are subject to a hold period and may not be traded until
the expiry thereof except as permitted by Applicable Law and the policies of the TSX Venture Exchange. In particular, each Purchaser
acknowledges that the certificates representing the Convertible Debenture and, if any Warrants are exercised or if the Convertible Debenture
is converted prior to the expiry of the statutory or any applicable TSX Venture Exchange imposed resale restrictions, the certificates
representing the Warrants and the Underlying Shares shall bear a legend or legends substantially in the following form and with the information
completed: “UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE [INSERT
THE DATE THAT IS 4 MONTHS AND A DAY AFTER THE DISTRIBUTION DATE].” and, (a) if such Purchaser is: (i) a director, officer or “Promoter”
(as defined in the Policies of the TSX Venture Exchange) of the Company; or (ii) a “Person” (as defined in the Policies of
the TSX Venture Exchange) holding securities carrying more than 10% of the voting rights attached to the Company’s securities both
immediately before and after the Offering, and who has elected or appointed or has the right to elect or appoint one or more directors
or “senior officers” (as defined in the Policies of the TSX Venture Exchange) of the Company, or (b) if the FT Shares are
issued at a price that is at a discount of more than 10% to the “Market Price” (as defined in the Policies of the TSX Venture
Exchange): “WITHOUT PRIOR WRITTEN APPROVAL OF TSX VENTURE EXCHANGE AND COMPLIANCE WITH ALL APPLICABLE SECURITIES LEGISLATION, THE
SECURITIES REPRESENTED BY THIS CERTIFICATE [for the Convertible Debenture and Warrant certificates add, AND ANY SECURITIES ISSUED ON
THE EXERCISE OR CONVERSION OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE,] MAY NOT BE SOLD, TRANSFERRED, HYPOTHECATED OR OTHERWISE
TRADED ON OR THROUGH THE FACILITIES OF TSX VENTURE EXCHANGE OR OTHERWISE IN CANADA OR TO OR FOR THE BENEFIT OF A CANADIAN RESIDENT UNTIL
[INSERT THE DATE THAT IS 4 MONTHS AND A DAY AFTER THE DISTRIBUTION DATE].”


 


(ii)
U.S. Provisions. Each Purchaser agrees to the imprinting, so long as is required by this Section 4.1, of a legend on any of the
Securities in the following form:


 


[NEITHER]
THIS SECURITY [NOR THE SECURITIES INTO WHICH THIS SECURITY IS [EXERCISABLE] [CONVERTIBLE]] HAS [NOT] BEEN REGISTERED WITH THE SECURITIES
AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL
TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY [AND THE SECURITIES
ISSUABLE UPON [EXERCISE] [CONVERSION] OF THIS SECURITY] MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED
BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER
THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.


 


(c)
Pledge. The Company acknowledges and agrees that the Purchasers may from time to time pledge pursuant to a bona fide margin agreement
with a registered broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an “accredited
investor” as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this Agreement and,
if required under the terms of such arrangement, the Purchasers may transfer pledge or secure Securities to the pledgees or secured parties.
Such a pledge or transfer would not be subject to approval of the Company and, to our knowledge, no legal opinion of legal counsel of
the pledgee, secured party or pledgor shall be required in connection therewith. At the appropriate Purchaser’s expense, the Company
will execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request in connection
with a pledge or transfer of the Securities.


 




    	 	30	 



     


    

 


(d)
Legend Removal. Certificates evidencing the Underlying Shares shall not contain any legend (“Unlegended Shares”)
(including the legends set forth in Section 4.1(b) hereof): (i) stipulated in NI 45-102 as of the date which falls four months and one
day from the date of issuance of the Convertible Debenture; (ii) required under the Securities Act while a registration statement covering
the resale of such security is effective under the Securities Act, (iii) if such Underlying Shares are eligible for sale under Rule 144,
without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such Underlying
Shares and without volume or manner-of-sale restrictions, or (iv) if such legend is not required under applicable requirements of the
Securities Act (including judicial interpretations and pronouncements issued by the staff of any agency or Trading Market with regard
to Applicable Law). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly after the Effective Date
if required by the Transfer Agent to effect the removal of the legend hereunder. If the Convertible Debenture is converted or any portion
of the Warrants are exercised (i) on or after such day which falls four months and one day from the date of issuance of the Convertible
Debenture, then such Underlying Shares shall be issued free of all Canadian legends; or (ii) at a time when there is an effective registration
statement to cover the resale of the Underlying Shares, or if such Underlying Shares may be sold under Rule 144 or if such legend is
not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued
by the staff of the Commission) then such Underlying Shares shall be issued free of all United States legends. The Company agrees that
following such time as all such legends are no longer required under this Section 4.1(d), it will, no later than five (5) Trading Days
following the delivery by such Purchaser to the Company or the Transfer Agent of a certificate representing Underlying Shares, as applicable,
issued with a restrictive legend (such fifth Trading Day, the “Legend Removal Date”), deliver or cause to be delivered
to such Purchaser a certificate representing such shares that is free from all restrictive and other legends (however, the Company shall
use reasonable best efforts to deliver such shares within two (2) Trading Days). The Company may not make any notation on its records
or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4. Certificates for Underlying
Shares subject to legend removal hereunder shall, if possible, be transmitted by the Transfer Agent to such Purchaser by crediting the
account of such Purchaser’s prime broker with the Depository Trust Company System as directed by such Purchaser.


 


(e)
Legend Removal Default. In addition to such Purchaser’s other available remedies, the Company shall pay to a Purchaser, in cash,
as partial liquidated damages and not as a penalty, for each $1,000 of Underlying Shares (based on the highest of the actual purchase
price or VWAP of the Common Stock on the date such Securities are submitted to the Transfer Agent) delivered for removal of the restrictive
legend and subject to Section 4.1(d), $10 per Trading Day for each Trading Day after the Legend Removal Date (increasing to $20 per Trading
Day after the fifth Trading Day) until such certificate is delivered without a legend. Nothing herein shall limit such Purchaser’s
right to pursue actual damages for the Company’s failure to deliver certificates representing any Securities as required by the
Transaction Documents, and such Purchaser shall have the right to pursue all remedies available to it at law or in equity including,
without limitation, a decree of specific performance and/or injunctive relief.


 




    	 	31	 



     


    

 


 


(f)
DWAC. In lieu of delivering physical certificates representing the Unlegended Shares, upon request of such Purchaser, and so long
as the certificates therefor do not bear a legend and such Purchaser is not obligated to return such certificate for the placement of
a legend thereon, the Company shall cause its transfer agent to electronically transmit the Unlegended Shares by crediting the account
of such Purchaser’s prime broker with the Depository Trust Company through its Deposit Withdrawal At Custodian system, provided
that the Common Stock is DTC eligible and the Company’s transfer agent participates in the Deposit Withdrawal at Custodian system.
Such delivery must be made on or before the Legend Removal Date.


 


(g)
Injunction. In the event a Purchaser shall request delivery of Unlegended Shares as described in this Section 4.1 and the Company
is required to deliver such Unlegended Shares, the Company may not refuse to deliver Unlegended Shares based on any claim that any Purchaser
or anyone associated or affiliated with any Purchaser has not complied with a Purchaser’s obligations under the Transaction Documents,
or for any other reason, unless an injunction or temporary restraining order from a court, on notice, restraining and or enjoining delivery
of such Unlegended Shares shall have been sought and obtained by the Company and the Company has posted a surety bond for the benefit
of such Purchaser in the amount of the greatest of (i) 120% of the amount of the aggregate purchase price of the Underlying Shares to
be subject to the injunction or temporary restraining order, or (ii) the VWAP of the Common Stock on the trading day before the issue
date of the injunction multiplied by the number of Unlegended Shares to be subject to the injunction shall remain in effect until the
completion of arbitration/litigation of the dispute and the proceeds of which shall be payable to such Purchaser to the extent such Purchaser
obtains judgment in such Purchaser’s favor.


 


(h)
Buy-In. In addition to any other rights available to a Purchaser, if the Company fails to deliver Unlegended Shares to a Purchaser
as required pursuant to this Agreement and after the Legend Removal Date such Purchaser, or a broker on such Purchaser’s behalf,
purchases (in an open market transaction or otherwise) Common Stock to deliver in satisfaction of a sale by such Purchaser of the Common
Stock which such Purchaser was entitled to receive in unlegended form from the Company (a “Buy-In”), then the Company
shall promptly pay in cash to such Purchaser (in addition to any remedies available to or elected by such Purchaser) the amount, if any,
by which (A) such Purchaser’s total purchase price (including brokerage commissions, if any) for the Common Stock so purchased
exceeds (B) the aggregate purchase price of the Common Stock delivered to the Company for reissuance as Unlegended Shares together with
interest thereon at a rate of 15% per annum accruing until such amount and any accrued interest thereon is paid in full (which amount
shall be paid as liquidated damages and not as a penalty). For example, if a Purchaser purchases Common Stock having a total purchase
price of $11,000 to cover a Buy-In with respect to $10,000 of purchase price of Shares delivered to the Company for reissuance as Unlegended
Shares, the Company shall be required to pay such Purchaser $1,000, plus interest, if any. A Purchaser shall provide the Company written
notice indicating the amounts payable to such Purchaser in respect of the Buy-In.


 


(i)
Plan of Distribution. Each Purchaser agrees with the Company that such Purchaser will sell any Securities pursuant to either the
registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom,
and that if Securities are sold pursuant to a registration statement, they will be sold in compliance with the plan of distribution set
forth therein, and acknowledges that the removal of the restrictive legend from certificates representing Securities as set forth in
this Section 4.1 is predicated upon the Company’s reliance upon this understanding.


 




    	 	32	 



     


    

 


4.2
Acknowledgment of Dilution. The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding
Common Stock, which dilution may be substantial under certain market conditions. The Company further acknowledges that its obligations
under the Transaction Documents, including, without limitation, its obligation to issue the Underlying Shares pursuant to the Transaction
Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the
effect of any such dilution or any claim the Company may have against a Purchaser and regardless
of the dilutive effect that such issuance may have on the ownership of the other stockholders of the Company.


 


4.3
Furnishing of Information; Public Information.


 


(a)
As long as the Convertible Debenture or Warrants are outstanding, the Company covenants to file all current and periodic reports required
to be filed in conjunction with all Applicable Law and the TSX Venture Exchange.


 


(b)
At any time commencing on the Closing Date and ending at such time that all of the Securities may be sold without the requirement for
the Company to be in compliance with Rule 144(c)(2) and otherwise without restriction or limitation pursuant to Rule 144, if the Company
shall fail for any reason to satisfy the current public information requirement under Rule 144(c) or subparagraph (a) above (a “Public
Information Failure”) then, in addition to such Purchaser’s other available remedies, the Company shall pay to such Purchaser,
in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the Securities,
an amount in cash equal to two percent (2.0%) of the aggregate principal amount of Convertible Debentures and accrued interest thereon
and purchase price of Warrant Shares held by such Purchaser on the day of a Public Information Failure and on every thirtieth (30th)
day (pro-rated for periods totaling less than thirty days) thereafter until the earlier of (a) the date such Public Information Failure
is cured and (b) such time that such public information is no longer required for the Purchasers to transfer Underlying Shares pursuant
to Rule 144. The payments to which a Purchaser shall be entitled pursuant to this Section 4.3(b) are referred to herein as “Public
Information Failure Payments.” Public Information Failure Payments shall be paid on the earlier of (i) the last day of the calendar
month during which such Public Information Failure Payments are incurred and (ii) the third (3rd) Business Day after the event or failure
giving rise to the Public Information Failure Payments is cured. In the event the Company fails to make Public Information Failure Payments
in a timely manner, such Public Information Failure Payments shall bear interest at the rate of 1.5% per month (prorated for partial
months) until paid in full. Nothing herein shall limit such Purchaser’s right to pursue actual damages for the Public Information
Failure, and such Purchaser shall have the right to pursue all remedies available to it at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief.


 


4.4
Integration. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would
require the registration under the Securities Act of the sale of the Securities or that would be integrated with the offer or sale of
the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior
to the closing of such other transaction or to effectuate such other transaction unless shareholder approval is obtained before the earlier
of the closing of such subsequent transaction or effectuation of such other transaction.


 




    	 	33	 



     


    

 


4.5
Conversion and Exercise Procedures. Each of the form of Notice of Exercise included in the Warrants and the form of Notice of
Conversion included in the Convertible Debenture Certificate set forth the totality of the procedures required of the Purchasers in order
to exercise the Warrants or convert the Convertible Debenture. No additional legal opinion, other information or instructions shall be
required of the Purchasers to exercise the Warrants or convert the Convertible Debenture. The Company shall honor exercises of the Warrants
and conversions of the Convertible Debenture and shall deliver Underlying Shares in accordance with the terms, conditions and time periods
set forth in the Transaction Documents.


 


4.6
Securities Laws Disclosure; Publicity. The Company shall, by 9:30 a.m. (New York City time) on the Trading Day of the Closing
Date, issue a press release. From and after the issuance of the press release, the Company represents to the Purchasers that it shall
have publicly disclosed all material, non-public information delivered to the Purchasers by the Company or any of the Subsidiaries, or
any of their respective officers, directors, employees or agents in connection with the transactions contemplated by the Transaction
Documents. The Company and the Purchasers shall consult with each other in issuing any press releases with respect to the transactions
contemplated hereby, and neither the Company nor the Purchasers shall issue any press release
nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of the Purchasers,
or without the prior consent of the Purchasers, with respect to any press release of the Company, which consent shall not unreasonably
be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other
party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose
the name of the Purchasers, or include the name of the Purchasers
in any filing with any Canadian or U.S. regulatory agency or Trading Market unless the name of the
Purchaser is already included in the body of the Transaction Documents, without the prior written consent of the
Purchasers.


 


4.7
Shareholder Rights Plan. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that a Purchaser is an “Acquiring Person” under any control share acquisition, business
combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect
or hereafter adopted by the Company, or that a Purchaser could be deemed to trigger the provisions
of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between
the Company and the Purchasers.


 


4.8
Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, the Company covenants and agrees that neither it, nor any other Person acting on its behalf, will provide the
Purchasers or their agents or counsel with any information that the Company believes constitutes material non-public information,
unless prior thereto the Purchasers shall have entered into a written agreement with the Company regarding the confidentiality and use
of such information. The Company understands and confirms that the Purchasers shall be relying on the foregoing covenant in effecting
transactions in securities of the Company.


 


4.9
Use of Proceeds. The Company shall use the net proceeds from the sale of the Offering hereunder substantially for the purposes
set forth on Schedule 4.9 hereto and shall not use such proceeds: (a) for the satisfaction of any portion of the Company’s
Indebtedness except as disclosed on Schedule 4.9, (b) for the redemption of any Common Stock or Common Stock Equivalents, (c)
for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations and any analogous Canadian laws.


 




    	 	34	 



     


    

 


4.10
Indemnification of Purchasers. Subject to the provisions of this Section 4.10, the Company will indemnify and hold each Purchaser
and their directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls a Purchaser (within
the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents,
members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a “Purchaser Party”) harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser Party may suffer or
incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company
in this Agreement or in the other Transaction Documents or (b) any action instituted against Purchaser Parties in any capacity, or any
of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect
to any of the transactions contemplated by the Transaction Documents (unless such action is based upon a breach of such Purchaser Party’s
representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may
have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser
Party which constitutes fraud, gross negligence, willful misconduct or malfeasance). If any action shall be brought against any Purchaser
Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company
in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable
to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the
defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that
(i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable
period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel, a
material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the
Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be
liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company’s prior
written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim,
damage or liability is attributable to any Purchaser Party’s breach of its material representations, warranties or covenants under
the Transaction Documents. The indemnification required by this Section 4.10 shall be made by periodic payments of the amount thereof
during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained
herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities
the Company may be subject to pursuant to law.


 


4.11
Reservation and Listing of Securities.


 


(a)
The Company shall maintain a reserve from its duly authorized Common Stock for issuance pursuant to the Transaction Documents in such
amount as may then be required to fulfill its obligations in full under the Transaction Documents, but not less than the Required Minimum.


 


(b)
If, on any date, the number of authorized but unissued (and otherwise unreserved) Common Stock is less than the Required Minimum on such
date, then the Board of Directors shall amend the Company’s certificate or articles of incorporation to increase the number of
authorized but unissued Common Stock to at least the Required Minimum at such time, as soon as possible and in any event not later than
the 60th day after such date.


 




    	 	35	 



     


    

 


(c)
The Company shall prior to the Closing, if applicable: (i) in the time and manner required by the principal Trading Market, prepare and
file with such Trading Market an additional shares listing application covering a number of Common Stock at least equal to the Required
Minimum on the date of such application, (ii) take all steps necessary to cause such Common Stock to be approved for listing or quotation
on such Trading Market as soon as possible thereafter, (iii) provide to the Purchasers evidence of such listing or quotation and (iv)
maintain the listing or quotation of such Common Stock on any date at least equal to the Required Minimum on such date on such Trading
Market or another Trading Market. The Company will take all action necessary to continue the listing or quotation and trading of its
Common Stock on a Trading Market until the later of (i) at least five years after the Closing Date, and (ii) for so long as the Convertible
Debenture or Warrants are outstanding, and will comply in all respects with the Company’s reporting, filing and other obligations
under the bylaws or rules of the Trading Market at least until five years after the Closing Date and for so long as the Convertible Debenture
and Warrants are outstanding. In the event the aforedescribed listing is not continuously maintained for five years after the Closing
Date and for so long as the Convertible Debenture or Warrants are outstanding (a “Listing Default”), then in addition
to any other rights the Purchasers may have hereunder or under Applicable Law, on the first day of a Listing Default and on each monthly
anniversary of each such Listing Default date (if the applicable Listing Default shall not have been cured by such date) until the applicable
Listing Default is cured, the Company shall pay to the Purchasers an amount in cash, as partial liquidated damages and not as a penalty,
equal to 2% of the aggregate outstanding Convertible Debenture principal and accrued interest, conversion price of Conversion Shares
and purchase price of Warrant Shares held by such Purchaser or which may be acquired upon exercise of Warrants on the day of a Listing
Default and on every thirtieth day (pro-rated for periods less than thirty days) thereafter until the date such Listing Default is cured.
If the Company fails to pay any liquidated damages pursuant to this Section in a timely manner, the Company will pay interest thereon
at a rate of 1.5% per month (pro-rated for partial months) to the Purchasers.


 


4.12
Filings. The Company agrees to timely all reports required under Applicable Securities Laws. The Company shall take such action
as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to
the Purchasers at the Closing under applicable securities or “Blue Sky” laws of the states of the United States, and shall
provide evidence of such actions promptly upon request of the Purchasers.


 


The
Purchasers further acknowledges and expressly consents to:


 


(a)
the disclosure of Personal Information by the Company to the TSX Venture Exchange pursuant to the TSX Venture Exchange Form 4B entitled
Private Placement Notice Form and other applicable regulatory authorities, as required; and


 


(b)
the collection, use and disclosure of Personal Information by the TSX Venture Exchange for such purposes described in Appendix 6B (a
copy of which is attached as Schedule F) or as otherwise may be identified by the TSX Venture Exchange, from time to time.


 


The
information provided by the Purchasers identifying among other things, the name, address, telephone number and email address of the Purchasers,
the number of Convertible Debenture being purchased hereunder, the Subscription Amount, and the exemption that the Purchasers are relying
on in purchasing the Purchased Securities will be disclosed to the Canadian securities regulatory authorities, and such information is
being indirectly collected by the Canadian securities regulatory authorities under the authority granted to it under Canadian securities
legislation. This information is being collected for the purposes of the administration and enforcement of Canadian securities legislation.
The Purchasers hereby authorize the indirect collection of such information by the Canadian securities regulatory authorities. In the
event a Purchaser has any questions with respect to the indirect collection of such information, such Purchaser should contact the BCSC
as follows:


 




    	 	36	 



     


    

 


British
Columbia Securities Commission

P.O. Box 10142, Pacific Centre

701 West Georgia Street

Vancouver, British Columbia V7Y 1L2

Inquiries: (604) 899-6854

Toll free in Canada: 1-800-373-6393

Facsimile: (604) 899-6581

Email: FOI-privacy@bcsc.bc.ca

Public official contact: FOI Inquiries


 


4.13
Subsequent Equity Sales.


 


(a)
Variable Priced. From the date hereof until such time as the Convertible Debenture or Warrants are no longer outstanding, the
Company will not, without the consent of the Purchasers, or have or allow to be outstanding, nor enter into any Equity Line of Credit
or similar agreement, issue or agree to issue floating or Variable Priced Equity Linked Instruments, nor any of the foregoing or equity
with price reset rights (subject to adjustment for stock splits, distributions, dividends, recapitalizations and the like) (collectively,
a “Variable Rate Transaction”) which is not in place as of the date hereof. For purposes hereof, “Equity
Line of Credit” shall include any transaction involving a written agreement between the Company and an investor or underwriter
whereby the Company has the right to “put” its securities to the investor or underwriter over an agreed period of time and
at an agreed price or price formula, and “Variable Priced Equity Linked Instruments” shall include: (A) any debt or
equity securities which are convertible into, exercisable or exchangeable for, or carry the right to receive additional Common Stock
or Common Stock Equivalents or any of the foregoing at a price that can be reduced either (1) at any conversion, exercise or exchange
rate or other price that is based upon and/or varies with the trading prices of or quotations for Common Stock at any time after the
initial issuance of such debt or equity security, or (2) with a fixed conversion, exercise or exchange price that is subject to being
reset at some future date at any time after the initial issuance of such debt or equity security due to a change in the market price
of the Common Stock since date of initial issuance, or upon the issuance of any debt, equity or Common Stock Equivalent, and (B) any
amortizing convertible security which amortizes prior to its maturity date, where the Company is required or has the option to (or any
investor in such transaction has the option to require the Company to) make such amortization payments in Common Stock which are valued
at a price that is based upon and/or varies with the trading prices of or quotations for Common Stock at any time after the initial issuance
of such debt or equity security (whether or not such payments in stock are subject to certain equity conditions). For purposes of determining
the total consideration for a convertible instrument (including a right to purchase equity of the Company) issued, subject to an original
issue or similar discount or which principal amount is directly or indirectly increased after issuance, the consideration will be deemed
to be the actual net cash amount received by the Company in consideration of the original issuance of such convertible instrument. For
so long as the Convertible Debenture is outstanding, the Company will not amend the terms of any securities or Common Stock Equivalents
or of any agreement outstanding or in effect as of the date of this Agreement pursuant to which same were or may be acquired, nor issue
any Common Stock or Common Stock Equivalents, without the consent of the Purchasers, if such issuance or the result of such amendment
would be at an effective price per share of Common Stock less than the higher of the Conversion Price or Exercise Price in effect at
the time of such issuance or amendment or result in the issuance of a greater amount of securities than prior to such amendment. The
restrictions and limitations in this Section 4.13 shall apply whether or not a Purchaser exercises its rights pursuant to Section 4.23
of this Agreement.


 




    	 	37	 



     


    

 


(b)
Lower Priced. From the date hereof until such time as the Convertible Debenture or Warrants are no longer outstanding, the Company
will not, without either (i) the consent of the Purchasers, or (ii) (A) having prepaid the Convertible Debenture pursuant to the terms
thereof, or (B) having first lowered the Conversion Price of the Convertible Debenture to such lower price with having obtained the necessary
regulatory approval, issue any Common Stock or Common Stock Equivalents with a conversion or exercise price lower than the Conversion
Price and Exercise Price then in effect.


 


4.14
Certain Transactions and Confidentiality. Each Purchaser for itself only, covenants that neither it, nor any Affiliate acting
on such Purchaser’s behalf or pursuant to any understanding with such Purchaser will execute any purchases or sales, including
Short Sales, of any of the Company’s securities during the period commencing with the execution of this Agreement and ending at
such time that the transactions contemplated by this Agreement are first publicly announced pursuant to a press release as described
in Section 4.6. Such Purchaser covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed
by the Company pursuant to a press release as described in Section 4.6, such Purchaser will maintain the confidentiality of the existence
and terms of this transaction and the information included in the Transaction Documents and the Disclosure Schedules. Notwithstanding
the foregoing, and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees
that (i) such Purchaser is not making any representation, warranty or covenant hereby that it will not engage in effecting transactions
in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant
to a press release as described in Section 4.6, (ii) such Purchaser shall not be restricted or prohibited from effecting any transactions
in any securities of the Company in accordance with Applicable Law from and after the time that the transactions contemplated by this
Agreement are first publicly announced pursuant to a press release, and (iii) such Purchaser shall not have any duty of confidentiality
to the Company or the Subsidiaries after the filing of the press release. Notwithstanding the foregoing, any Purchaser is a multi-managed
investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s assets wherein the portfolio
managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s
assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made
the investment decision to purchase the Securities covered by this Agreement.


 


4.15
Registration Rights. The Company and Purchaser will enter into the Registration Rights Agreement.


 


4.16
Purchaser’s Exercise Limitations. The Company shall not effect any exercise of the rights granted in this Agreement, and
any Purchaser shall not have the right to exercise any portion of such rights granted in this Agreement to the extent that after giving
effect to such exercise, such Purchaser (together with such Purchaser’s Affiliates, and any other Persons acting as a group together
with such Purchaser or any of such Purchaser’s Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation
(as defined in the Convertible Debenture), applied in the manner set forth in the Convertible Debenture. In such event the right by such
Purchaser to benefit from such rights or receive shares in excess of the Beneficial Ownership Limitation shall be held in abeyance until
such times as such excess shares shall not exceed the Beneficial Ownership Limitation.


 


4.17
Maintenance of Property/Insurance. The Company shall keep all of its property, which is necessary or useful to the conduct of
its business, in good working order and condition, ordinary wear and tear excepted and insured by insurers of recognized financial responsibility
against such losses and risks and in such amounts as are prudent and customary for the businesses of the Company and Subsidiary. From
and after the Closing Date and for so long as any Securities are held by any Purchaser, the Company will maintain directors and officers
insurance coverage at least equal to the aggregate Subscription Amount.


 




    	 	38	 



     


    

 


4.18
Preservation of Corporate Existence. The Company and each Subsidiary shall preserve and maintain its corporate existence, rights,
privileges and franchises in the jurisdiction of its incorporation, and qualify and remain qualified, as a foreign Company in each jurisdiction
in which such qualification is necessary in view of its business or operations and where the failure to qualify or remain qualified might
reasonably have a Material Adverse Effect upon the financial condition, business or operations of the Company taken as a whole.


 


4.19
DTC Program. At all times that Convertible Debenture or Warrants are outstanding, the Company shall employ as the transfer agent
for its Common Stock and Underlying Shares a participant in the Depository Trust Company Automated Securities Transfer Program and, if
possible, cause the Common Stock and Underlying Shares to be transferable pursuant to such program.


 


4.20
Reimbursement. If a Purchaser becomes involved in any capacity in any Proceeding by or
against any Person who is a stockholder of the Company (except as a result of sales, pledges, margin sales and similar transactions by
such Purchaser to or with any current stockholder), solely as a result of such Purchaser’s acquisition of the Securities under
this Agreement, the Company will reimburse such Purchaser for its reasonable legal and other expenses (including the cost of any investigation
preparation and travel in connection therewith) incurred in connection therewith, as such expenses are incurred. The reimbursement obligations
of the Company under this paragraph shall be in addition to any liability which the Company may otherwise have, shall extend upon the
same terms and conditions to any Affiliates of such Purchaser who are actually named in such action, proceeding or investigation, and
partners, directors, agents, employees and controlling persons (if any), as the case may be, of such Purchaser and any such Affiliate,
and shall be binding upon and inure to the benefit of any successors, assigns, heirs and personal representatives of the Company, such
Purchaser and any such Affiliate and any such Person. The Company also agrees that neither the Purchasers nor any such Affiliates, partners,
directors, agents, employees or controlling persons shall have any liability to the Company or any Person asserting claims on behalf
of or in right of the Company solely as a result of acquiring the Securities under this Agreement.


 


4.21
Most Favored Nation Provision. For as long as the Convertible Debenture or Warrants are outstanding, in the event that the Company
issues or sells any Common Stock or Common Stock Equivalents with terms that a Purchaser then holding outstanding Convertible Debenture
or Warrants reasonably believes are more favorable to such investors than are the terms of the Convertible Debenture or the Warrants
(the “MFN Securities”), upon notice to the Company by a Purchaser within five (5) Trading Days after notice to such
Purchaser by the Company of such issuance or sale, the Company will use commercially reasonable efforts to obtain the approval of the
TSX Venture Exchange and any additional required regulatory approval to amend the terms of the Convertible Debenture or Warrants as required,
as the case may be, of such Purchaser only so as to give such Purchaser the benefit of such more favorable terms or conditions. If the
Company fails to obtain such regulatory approvals and the approval of the TSX Venture Exchange, then absent such approval the Company
is forbidden to issue the MFN Securities. This Section 4.21 shall not apply with respect to an Exempt Issuance. The Company shall provide
the Purchasers with notice of any such issuance or sale not later than ten (10) Trading Days before such issuance or sale.


 


4.22
Notice of Disqualification Events. The Company will notify the Purchasers in writing, prior to the Closing Date of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, become a Disqualification Event
relating to any Issuer Covered Person not otherwise disclosed herein or in the Public Reports.


 




    	 	39	 



     


    

 


4.23
Participation in Future Financing.


 


(a)
From the date hereof until the date that the Convertible Debenture or Warrants are outstanding, upon any issuance by the Company or any
of the Subsidiaries of Common Stock or Common Stock Equivalents for cash consideration, indebtedness or a combination of units thereof
(a “Subsequent Financing”), the Purchasers shall have the right to participate in up to an amount of the Subsequent
Financing equal to 100% of the Subsequent Financing (the “Participation Maximum”) on the same terms, conditions and
price provided for in the Subsequent Financing.


 


(b)
At least ten (10) Trading Days prior to the closing of the Subsequent Financing, the Company shall deliver to the Purchasers a written
notice of its intention to effect a Subsequent Financing with terms (“Subsequent Financing Notice”). The Subsequent
Financing Notice shall describe in reasonable detail the proposed terms of such Subsequent Financing, the amount of proceeds intended
to be raised thereunder and the Person or Persons through or with whom such Subsequent Financing is proposed to be effected and shall
include a term sheet or similar document relating thereto as an attachment.


 


(c)
A Purchaser, if participating in such Subsequent Financing, must provide written notice to the Company by not later than 5:30 p.m. (New
York City time) on the tenth (10th) day after such Purchaser has received the Subsequent Financing Notice that such Purchaser
is willing to participate in the Subsequent Financing, the amount of such Purchaser’s participation, and representing and warranting
that such Purchaser has such funds ready, willing, and available for investment on the terms set forth in the Subsequent Financing Notice.
If the Company receives no such notice from a Purchaser as of such tenth (10th) day, such Purchasers shall be deemed to have
notified the Company that it/they do(es) not elect to participate and the Company may thereafter complete such Subsequent Financing without
any participation by such Purchaser(s).


 


(d)
The Company and the Purchasers agree that if a Purchaser elects to participate in the Subsequent Financing, the transaction documents
related to the Subsequent Financing shall not include any term or provision whereby the Purchasers shall be required to agree to any
restrictions on trading as to any of the Securities purchased hereunder or be required to consent to any amendment to or termination
of, or grant any waiver, release or the like under or in connection with, this Agreement, without the prior written consent of the Purchasers.


 


(e)
Notwithstanding anything to the contrary in this Section 4.23 and unless otherwise agreed to by the Purchasers, the Company shall either
confirm in writing to the Purchasers that the transaction with respect to the Subsequent Financing has been abandoned or shall publicly
disclose its intention to issue the securities in the Subsequent Financing, in either case in such a manner such that the Purchasers
will not be in possession of any material, non-public information, by the tenth (10th) Business Day following delivery of
the Subsequent Financing Notice. If by such tenth (10th) Business Day, no public disclosure regarding a transaction with respect
to the Subsequent Financing has been made, and no notice regarding the abandonment of such transaction has been received by the Purchasers,
such transaction shall be deemed to have been abandoned and the Purchasers shall not be deemed to be in possession of any material, non-public
information with respect to the Company or any of the Subsidiaries.


 


4.24
Equal Treatment of Purchasers. No consideration (including any modification of any Transaction Document) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of any of this Agreement unless the same consideration
is also offered on a ratable basis to all of the parties to this Agreement. For clarification purposes, this provision constitutes a
separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company
to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect
to the purchase, disposition or voting of Securities or otherwise.


 




    	 	40	 



     


    

 


4.25
Duration of Undertakings. Unless otherwise stated in this Article IV, all of the Company’s undertakings, obligations and
responsibilities set forth in Article IV of this Agreement shall remain in effect for so long as any Securities remain outstanding.


 


ARTICLE
V.


MISCELLANEOUS


 


5.1
Termination. This Agreement may be terminated by either Party by written notice to the
other Party, if the Closing has not been consummated on or before April 30, 2022; provided, however, that such termination will
not affect the right of any party to sue for any breach by any other party.


 


5.2
Fees and Expenses. At the Closing, the Company has agreed to pay G&M for the legal fees in connection with the Closing in
the amount of U.S. $40,000 . Except as expressly set forth in the Transaction Documents, each party shall be responsible for and pay
the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party
incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall reimburse the Purchasers
for all expenses incurred in connection with UCC, lien, judgment, tax and similar searches, if any, conducted in connection with the
Offering. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of
any instruction letter delivered by the Company and any conversion or exercise notice delivered by the Purchasers), stamp taxes and other
taxes and duties levied in connection with the delivery of any Securities to the Purchasers.


 


5.3
Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding
of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written,
with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.


 


5.4
Notices. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be
in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified,
return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted
by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most
recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a)
upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address
or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the
first business day following such delivery (if delivered other than on a business day during normal business hours where such notice
is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed
to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be:
(i) if to the Company, to: Western Magnesium Corp., Suite 900 - 580 Hornby Street, British Columbia, Canada V6C 3B6, Attn: Sam Ataya,
Chief Executive Officer, email: sataya@westmagcorp.com, with a copy by email only to: Gowling WLG (Canada) LLP, Suite 2300, 550 Burrard
Street, Vancouver, British Columbia, Canada V6C 2B5, Attn: Brett A. Kagetsu, email: brett.kagetsu@gowlingwlg.com, and (ii) if to the
Purchasers, to: the address and email address indicated on the signature pages hereto, with an additional copy by email only to (which
shall not constitute notice): Grushko & Mittman, P.C., 1800 Rockaway Avenue, Suite 206, Hewlett, New York 11557, email: counslers@grushkomittman.com.


 




    	 	41	 



     


    

 


5.5
Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and the Purchasers holding at least a majority in interest of the Securities then
outstanding, which must include Alpha Capital Anstalt, so long as Alpha Capital Anstalt holds Convertible Debentures with an aggregate
principal amount of at least $50,000 (the “Majority in Interest”), or, in the case of a waiver, by the party against
whom enforcement of any such waived provision is sought. Whenever the term “consent of the Purchasers” or a similar term
is employed herein, it shall mean the consent of a Majority in Interest. No waiver of any default with respect to any provision, condition
or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver
of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder
in any manner impair the exercise of any such right.


 


5.6
Headings; Dollar Amounts. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not
be deemed to limit or affect any of the provisions hereof. All dollar amounts are in US dollars, unless otherwise specified herein.


 


5.7
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of the Purchasers (other than by merger). Following the Closing, each Purchaser may assign any
or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers
any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions
of the Transaction Documents that apply to such Purchaser.


 


5.8
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise
set forth in Section 4.10.


 


5.9
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the State of Delaware. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the State of Delaware for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction
Documents), and hereby irrevocably waives, and agrees not to assert in any action, suit or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such
proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action
or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party
at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service
of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner
permitted by law. If either party shall commence an action or proceeding to enforce any provisions of the Transaction Documents, then,
in addition to the obligations of the Company under Section 4.10, the prevailing party in such action, suit or proceeding shall be reimbursed
by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such action or proceeding.


 




    	 	42	 



     


    

 


5.10
Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature
page were an original thereof.


 


5.11
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.


 


5.12
Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) any of the other Transaction Documents, whenever a Purchaser exercises a right, election, demand or option under a Transaction Document
and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may, at any
time prior to the Company’s performance of such obligations, rescind or withdraw, in its sole discretion from time to time upon
written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and
rights; provided, however, that in the case of a rescission of a conversion of the Convertible Debenture or exercise of
a Warrant, such Purchaser shall be required to return any Common Stock subject to any such rescinded conversion or exercise notice concurrently
with the return to such Purchaser of the aggregate Conversion Price or Exercise Price, as applicable, paid to the Company for such Underlying
Shares, and the restoration of such Purchaser’s right to acquire such shares pursuant to the Convertible Debenture or Warrant,
as applicable (including, issuance of a replacement Convertible Debenture Certificate or Warrant Certificate, respectively, evidencing
such restored right).


 


5.13
Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.


 


5.14
Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction
Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that
a remedy at law would be adequate.


 




    	 	43	 



     


    

 


5.15
Payment Set Aside. To the extent that the Company makes a payment or payments to a Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by
or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.


 


5.16
Usury. To the extent it may lawfully do so, the Company hereby agrees not to insist upon or plead or in any manner whatsoever
claim, and will resist any and all efforts to be compelled to take the benefit or advantage of, usury laws wherever enacted, now or at
any time hereafter in force, in connection with any claim, action or proceeding that may be brought by a Purchaser in order to enforce
any right or remedy under any Transaction Document. Notwithstanding any provision to the contrary contained in any Transaction Document,
it is expressly agreed and provided that the total liability of the Company under the Transaction Documents for payments in the nature
of interest shall not exceed the maximum lawful rate authorized under Applicable Law (the “Maximum Rate”), and, without
limiting the foregoing, in no event shall any rate of interest or default interest, or both of them, when aggregated with any other sums
in the nature of interest that the Company may be obligated to pay under the Transaction Documents exceed such Maximum Rate. It is agreed
that if the maximum contract rate of interest allowed by law and applicable to the Transaction Documents is increased or decreased by
statute or any official governmental action subsequent to the date hereof, the new maximum contract rate of interest allowed by law will
be the Maximum Rate applicable to the Transaction Documents from the Closing Date thereof forward, unless such application is precluded
by Applicable Law. If under any circumstances whatsoever, interest in excess of the Maximum Rate is paid by the Company to a Purchaser
with respect to indebtedness evidenced by the Transaction Documents, such excess shall be applied by such Purchaser to the unpaid principal
balance of any such indebtedness or be refunded to the Company, the manner of handling such excess to be at such Purchaser’s election.


 


5.17
Liquidated Damages. The Company’s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts
have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.


 


5.18
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.


 


5.19
Construction. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against
the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each
and every reference to share prices and Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward
stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this
Agreement.


 




    	 	44	 



     


    

 


5.20
WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY,
THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. 


 


5.21
Equitable Adjustment. Trading volume amounts, price/volume amounts, the amount of Warrants, the Conversion Price, Exercise Prices
and similar figures in the Transaction Documents shall be equitably adjusted (but without duplication) to offset the effect of stock
splits, similar events and as otherwise described in this Agreement, the Convertible Debenture and Warrants.


 


5.22
Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as
a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way
acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of
this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional
party in any proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to
communicate with the Company through G&M. The Company has elected to provide all Purchasers with the same terms and Transaction Documents
for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood
and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser,
solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers. In the event circumstances
do not enable or allow the Company to fulfill its obligation in full to all Purchasers, then the Company shall fulfill its obligations
to multiple Purchasers having the same rights, pro rata to each such affected Purchaser’s Subscription Amount actually delivered
to the Company.


 


(Signature
Pages Follow)


 




    	 	45	 



     


    

 


IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.


 


	WESTERN
                                            MAGNESIUM CORP.

    
	Address
                                            for Notice:

     

    Suite
    900 - 580 Hornby Street

    Vancouver,
    British Columbia

    Canada V6C 3B6

    Attention: Sam Ataya

    Email: sataya@westmagcorp.com



 


	By:	/s/
    Sam Ataya	 
	Name:
    	Sam
    Ataya	 
	Title:
    	President
    and Chief Executive Officer	 


 


With
a copy to (which shall not constitute notice):


 


Gowling
WLG (Canada) LLP

Suite 2300, 550 Burrard Street

Vancouver, British Columbia

Canada V6C 2B5

Email: brett.kagetsu@gowlingwlg.com


 


And
to:


 


Anthony
L.G., PLLC


625
N. Flagler Drive, Suite 600


West
Palm Beach, FL


USA
33401


Email:
LAnthony@AnthonyPLLC.com


 


[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK


 


SIGNATURE
PAGES FOR PURCHASERS FOLLOWS]


 




    	 	46	 



     


    

 


[PURCHASER
SIGNATURE PAGE TO WESTERN MAGNESIUM CORP.


SECURITIES
PURCHASE AGREEMENT]


 


IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by its authorized signatory as of
the date indicated above.


 


Name
of Purchaser: Alpha Capital Anstalt


 


Signature
of Authorized Signatory of Purchaser: /s/ Lucas Mair


 


Name
of Authorized Signatory: Lucas Mair


 


Title
of Authorized Signatory: Director


 


Email
Address of Authorized Signatory: [***]


 


Telephone
Number of Authorized Signatory: [***]


 


Residential
or Head Office Address of the Purchaser: [***]


 


Address
for Notice to Purchaser: [***]


 


	Convertible
    Debenture principal amount:	$2,000,000
	 


 




    	 	47	 



     


    

 


	SCHEDULE
	 	TITLE

	 	 	 
	Exhibit
    A	 	Form
    of Convertible Debenture Certificate
	 	 	 
	Exhibit
    B	 	Form
    of Warrant Certificate
	 	 	 
	Exhibit
                                            C
	 	Payment
                                            Instructions

	 	 	 
	Exhibit
    D	 	Registration
    Rights Agreement
	 	 	 
	Schedule
    A	 	Information
    Sheet
	 	 	 
	Appendix
    A to Schedule A	 	TSX
    Venture Exchange Form 4C – Corporate Placee Registration Form
	 	 	 
	Schedule
    B	 	Registration
    and Delivery Instructions
	 	 	 
	Schedule
    C	 	Outside
    of Canada Purchaser Certificate
	 	 	 
	Schedule
    D	 	Certification
    of U.S. Purchaser
	 	 	 
	Schedule
    E	 	TSX
    Venture Exchange Appendix 6B Acknowledgement – Personal Information
	 	 	 
	Schedule
    3.1(a)	 	Subsidiaries
	 	 	 
	Schedule
    3.1(g)	 	Capitalization
	 	 	 
	Schedule
    3.1(i)	 	Material
    Changes; Undisclosed Events, Liabilities or Developments
	 	 	 
	Schedule
    3.1(z)	 	Solvency
	 	 	 
	Schedule
    3.1(ll)	 	Indebtedness
    and Seniority
	 	 	 
	Schedule
    4.9	 	Use
    of Proceeds



 



    	 	48	 



     


    

 


Exhibit
A

Form of Convertible Debenture Certificate


 


See Exhibit 4.1 to this Form 8-K.


 




    	 	Ex A-1	 



     


    

 


Exhibit
B

Form of Warrant Certificate


 


See Exhibit 10.2 to this Form 8-K.


 




    	 	Ex B-1	 



     


    

 


Exhibit
C

Payment Instructions


 


The
Purchaser will make payment arrangements for the Subscription Amount in a certified cheque, bank draft or wire transfer or other acceptable
form of payment to the Company for the total aggregate Subscription Amount of the Convertible Debenture subscribed for, payable to “Western
Magnesium Corporation” or such other person as the Company may advise the Purchaser. If you are sending a certified cheque
or bank draft, please make the same payable to the Company and deliver to:


 


Western
Magnesium Corporation

Suite 900 - 580 Hornby Street,

Vancouver, British Columbia

Canada V6C 3B6

Attention: Lisa Maxwell

T: 604 839-7985

E: lmaxwell@westmagcorp.com


 


If
you are sending such funds by wire transfer, please note the following wire transfer instructions:


 


	WIRE
    TRANSFER INSTRUCTIONS	 	 
	Account
    in the name of:	 	Western
    Magnesium Corporation
	Bank
    Name:	 	Bank
    of America, N.A., NY
	Bank
    Address:	 	New
    York, United States
	Bank
    Telephone:	 	1-888-852-5000
	US
    Dollar Account Number:	 	[***]
	Transit
    Number:	 	N/A
	Financial
    Institution Number:	 	N/A
	Swift
    Code:	 	BOFAUS3N
	ABA
    Routing:	 	026009593


 




    	 	Ex C-1	 



     


    

 


SCHEDULE
A


 


INFORMATION
SHEET


 


Information
to be completed by the Purchaser:


 


	A.	Registration
    Form
	 	 
	The
    Purchaser, if not an individual, either [check appropriate box]:
	 
	☐	has
    previously filed with the TSX Venture Exchange a Form 4C, Corporate Placee Registration Form, represents and warrants that there
    has been no change to any of the information in the Corporate Placee Registration Form previously filed with the TSX Venture Exchange
    up to the date hereof; or
	 	 
	☐	hereby
    delivers a completed Form 4C, Corporate Placee Registration Form, in the form attached as Appendix A to this Schedule B to the Company
    for filing with the Exchange.
	 	 
	B.	Present
    Ownership of Securities
	 	 
	The
    Purchaser either [check appropriate box]:
	 
	☐	does
    not own, directly or indirectly, or exercise control or direction over, any Common Stock of the Company or securities convertible
    into Common Stock of the Company; or
	 	 
	☐	owns,
    directly or indirectly, or exercises control or direction over, ____________ outstanding common shares of the Company and convertible
    securities entitling the Purchaser to acquire additional common shares of the Company which, if converted, in the aggregate would
    represent ______________ common shares of the Company.
	 	 
	C.	Insider
    Status
	 	 
	The
    Purchaser either [check appropriate box]:
	 
	☐	is
    an “Insider” of the Company as defined in the policies of the Exchange:
	 	 
	 	(a)	a
    director or senior officer of the Company (or a subsidiary of the Company);
	 	 	 
	 	(b)	any
    Person who beneficially owns, directly or indirectly, voting securities of the Company or who exercises control or direction over
    voting securities of the Company or a combination of both carrying more than 10% of the voting rights attached to all voting securities
    of the Company for the time being outstanding, or
	 	 	 
	 	(c)	a
    director or senior officer of an Insider of the Company.
	 	 	 
	☐	is
    not an Insider of the Company.


 




    	 	Sch A-1	 



     


    

 


	D.	Member
    of “Pro Group”
	 	 
	The
    Purchaser either [check appropriate box]:
	 
	☐	is
    a Member of the “Pro Group” as defined in the Corporate Finance Manual of the Stock Exchange, as follows:
	 	 
	 	(a)	subject
    to subparagraphs (b), (c) and (d), either individually or as a group:
	 	 	 
	 	 	(i)	a
    “Member” (defined in Rule A.1.00 of the Rules and Trading Policies of the TSX Venture Exchange as a Company or individual
    (a “Person”) who has executed the Members’ Agreement, as amended from time to time, and is accepted as and
    becomes a member of the TSX Venture Exchange under the Exchange Requirements);
	 	 	 	 
	 	 	(ii)	employees
    of the Member;
	 	 	 	 
	 	 	(iii)	partners,
    officers or directors of the Member;
	 	 	 	 
	 	 	(iv)	Affiliates
    of the Member; and
	 	 	 	 
	 	 	(v)	Associates
    of any parties referred to in subparagraphs (i) through (iv);
	 	 	 	 
	 	(b)	the
    TSX Venture Exchange may, in its discretion, include a Person or party in the Pro Group for the purposes of a particular calculation
    where the TSX Venture Exchange determines that the Person is not acting at arm’s length to the Member;
	 	 	 
	 	(c)	the
    TSX Venture Exchange may, in its discretion, exclude a Person from the Pro Group for the purposes of a particular calculation where
    the TSX Venture Exchange determines that the person is acting at arm’s length of the Member;
	 	 	 
	 	(d)	the
    TSX Venture Exchange may deem a person who would otherwise be included in the Pro Group pursuant to subparagraph (a) to be excluded
    from the Pro Group where the TSX Venture Exchange determines that:
	 	 	 
	 	 	(i)	the
    Person is an affiliate or associate of the member acting at arm’s length of the Member;
	 	 	 	 
	 	 	(ii)	the
    associate or affiliate has a separate corporate and reporting structure;
	 	 	 	 
	 	 	(iii)	there
    are sufficient controls on information flowing between the Member and the associate or affiliate; and
	 	 	 	 
	 	 	(iv)	the
    Member maintains a list of such excluded persons; or
	 	 	 	 
	☐	is
    not a member of the Pro Group.


 


	E.	Registrant
	 	 
	The
    Purchaser either [check appropriate box]:
	 
	☐	is
    a “registrant” as such term is defined in the Securities Act (British Columbia); or
	 	 
	☐	is
    not a “registrant”.


 




    	 	Sch A-2	 



     


    

 


APPENDIX
A TO SCHEDULE A


 





 


FORM
4C


CORPORATE
PLACEE REGISTRATION FORM


 


This
Form will remain on file with the Exchange and must be completed if required under section 4(b) of Part II of Form 4B. The corporation,
trust, portfolio manager or other entity (the “Placee”) need only file it on one time basis, and it will be referenced for
all subsequent Private Placements in which it participates. If any of the information provided in this Form changes, the Placee must
notify the Exchange prior to participating in further placements with Exchange listed Issuers. If as a result of the Private Placement,
the Placee becomes an Insider of the Issuer, Insiders of the Placee are reminded that they must file a Personal Information Form (2A)
or, if applicable, Declarations, with the Exchange.


 


	1.	Placee
    Information:
	 	 
	(a)	Name:
    ___________________________________________________________________________________
	 	 
	(b)	Complete
    Address: _________________________________________________________________________
	 	 
	(c)	Jurisdiction
    of Incorporation or Creation: _________________________________________________________
	 	 
	2.	(a)	Is
    the Placee purchasing securities as a portfolio manager: (Yes/No)? ________________
	 	 
	 	(b)	Is
    the Placee carrying on business as a portfolio manager outside of Canada:
	 	 	(Yes/No)?
    __________
	 	 
	3.	If
    the answer to 2(b) above was “Yes”, the undersigned certifies that:
	 	 
	 	(a)	it
    is purchasing securities of an Issuer on behalf of managed accounts for which it is making the investment decision to purchase the
    securities and has full discretion to purchase or sell securities for such accounts without requiring the client’s express
    consent to a transaction;
	 	 
	 	(b)	it
    carries on the business of managing the investment portfolios of clients through discretionary authority granted by those clients
    (a “portfolio manager” business) in ____________________ [jurisdiction], and it is permitted by law to carry on a portfolio
    manager business in that jurisdiction;
	 	 	 
	 	(c)	it
    was not created solely or primarily for the purpose of purchasing securities of the Issuer;
	 	 	 
	 	(d)	the
    total asset value of the investment portfolios it manages on behalf of clients is not less than CAD$20,000,000; and
	 	 	 
	 	(e)	it
    has no reasonable grounds to believe, that any of the directors, senior officers and other insiders of the Issuer, and the persons
    that carry on investor relations activities for the Issuer has a beneficial interest in any of the managed accounts for which it
    is purchasing.


 




    	 	Sch AA-1	 



     


    

 


Appendix
A to Schedule A


 


	4.	If
    the answer to 2(a). above was “No”, please provide the names and addresses of Control Persons of the Placee:








	Name
    *	 	City	 	Province
    or State	 	Country
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 


 


*
If the Control Person is not an individual, provide the name of the individual that makes the investment decisions on behalf of the Control
Person.


 


	5.	Acknowledgement
    - Personal Information and Securities Laws


 


	 	(a)	“Personal
    Information” means any information about an identifiable individual, and includes information contained in sections 1, 2 and
    4, as applicable, of this Form.


 


The
undersigned hereby acknowledges and agrees that it has obtained the express written consent of each individual to:


 


	 	(i)	the
    disclosure of Personal Information by the undersigned to the Exchange (as defined in Appendix 6B) pursuant to this Form; and
	 	 	 
	 	(ii)	the
    collection, use and disclosure of Personal Information by the Exchange for the purposes described in Appendix 6B or as otherwise
    identified by the Exchange, from time to time.


 


	 	(b)	The
    undersigned acknowledges that it is bound by the provisions of applicable Securities Law, including provisions concerning the filing
    of insider reports and reports of acquisitions.


 


Dated
and certified (if applicable), acknowledged and agreed, at ______________________________________________ on _____________________________________________


 


	 	 
	 	(Name
    of Purchaser - please print)
	 	 
	 	 
	 	(Authorized
    Signature)
	 	 
	 	 
	 	(Official
    Capacity - please print)
	 	 
	 	 
	 	(Please
    print name of individual whose signature appears above)


 


THIS
IS NOT A PUBLIC DOCUMENT


 




    	 	Sch AA-2	 



     


    

 


SCHEDULE
B


 


REGISTRATION
AND DELIVERY INSTRUCTIONS


 


	Account
    Registration Information:
	 
	 
	(Name)
	 
	 
	(Account
    Reference, if applicable)
	 
	 
	(Address,
    including Postal Code)
	 
	 
	 
	Delivery
    Instructions:
	 
	 
	(Name)
	 
	 
	(Account
    Reference, if applicable)
	 
	 
	(Address,
    including Postal Code)
	 
	 
	 
	 
	(Telephone
    Number)
	 
	(Contact
    Name)


 




    	 	Sch B-1	 



     


    

 


SCHEDULE
C


 


OUTSIDE
OF CANADA PURCHASER CERTIFICATE

(Purchaser Resident in a Jurisdiction Outside of Canada)


 


	TO:	Western
    Magnesium Corporation (the “Company”)
	 	 
	RE:	Private
    Placement (the “Offering”) of Convertible Debenture of the Company (the “Purchased Securities”) 


 


The
undersigned Purchaser represents, covenants and certifies to you that:


 


	1.	the
    Purchaser (and if acting as agent for a disclosed principal, such disclosed principal) is not a resident of Canada or subject to
    applicable Canadian securities laws and the decision to purchase the Purchased Securities was taken in the Purchaser’s jurisdiction
    of residence;
	 	 
	2.	the
    issuance of Purchased Securities to the Purchaser (or its disclosed principal, if any) may be effected by the Company without the
    necessity of the filing of a registration statement, prospectus or any document with or obtaining any approval from or effecting
    any registration with any governmental entity or similar regulatory authority having jurisdiction over the Purchaser (or its disclosed
    principal, if any) and will not cause the Company to become subject to, or require it to comply with, any disclosure (including continuous
    disclosure reporting obligations), prospectus, filing or reporting requirements under any applicable laws of the Purchaser’s
    jurisdiction of residence;
	 	 
	3.	the
    Purchaser (and if acting as agent for a disclosed principal, such disclosed principal) is knowledgeable of, or has been independently
    advised as to, the application or jurisdiction of the securities laws of the Purchaser’s jurisdiction of residence which would
    apply to the purchase of the Purchased Securities;
	 	 
	4.	the
    Purchaser (and if acting as agent for a disclosed principal, such disclosed principal), is purchasing the Purchased Securities pursuant
    to exemptions from the prospectus and registration requirements (or their equivalent) under the applicable Securities Laws of the
    Purchaser’s jurisdiction of residence or, if such is not applicable, each is permitted to purchase the Purchased Securities
    under the applicable securities laws of the Purchaser’s jurisdiction of residence without the need to rely on an exemption;
	 	 
	5.	the
    Purchaser (and if acting as agent for a disclosed principal, such disclosed principal), will not sell, transfer or dispose of the
    Purchased Securities except in accordance with all applicable laws, including applicable securities laws of Canada and the United
    States, as applicable, and the Purchaser acknowledges that the Company shall have no obligation to register any such purported sale,
    transfer or disposition which violates applicable securities laws;
	 	 
	6.	the
    issuance of the Purchased Securities, and the Purchaser (and if the Purchaser is acting as agent for a disclosed principal, such
    disclosed principal) complies with the requirements of all applicable laws in the jurisdiction of its residence; and
	 	 
	7.	the
    Purchaser will provide such evidence of compliance with all such matters as the Company, or its counsel may request, including a
    certificate or opinion of local counsel from the Purchaser’s jurisdiction of residence which will confirm the matters in subsections
    1 to 4 to the satisfaction of the Company, acting reasonably.


 


[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]


 




    	 	Sch C-1	 



     


    

  


SCHEDULE
C - OUTSIDE OF CANADA


PURCHASER
CERTIFICATE


 


The
Purchaser acknowledges and agrees that the above representations and warranties will be true and correct both as of the execution of
this certificate and as of the Closing of the purchase and sale of the Purchased Securities and that such representations and warranties
will survive the completion of the purchase of the Purchased Securities. If any such representations shall not be true and accurate prior
to the Closing Date, the undersigned shall give immediate written notice of such fact to the Company prior to the Closing Date.


 


	Dated:
    ___________________________________ 	,
    2022	 	Signed:
    	________________________________________
	 	 	 
	 	 	 
	 Witness
                                            (If Purchaser is an Individual)
	 	Print
    the name of Purchaser
	 	 	 
	 	 	 
	Print
    Name of Witness	 	If
                                            Purchaser is not an Individual,

                                            print name and title of Authorized Signing Officer



 




    	 	Sch C-2	 



     


    

 


SCHEDULE
D


 


CERTIFICATION
OF U.S. PURCHASER


 


	TO:	WESTERN
    MAGNESIUM CORP. (the “Issuer”)
	 	 
	RE:	SUBSCRIPTION
    FOR SECURITIES OF THE ISSUER


 


Capitalized
terms not specifically defined in this certification have the meaning ascribed to them in the Securities Purchase Agreement to which
this Schedule D is attached. In the event of a conflict between the terms of this certification and such Securities Purchase Agreement,
the terms of this certification shall prevail.


 


In
addition to the covenants, representations and warranties contained in the Securities Purchase Agreement to which this Schedule E is
attached, the undersigned Purchaser covenants, represents and warrants to the Issuer that:


 


	(a)	It
    is (i) a U.S. Person or a person in the United States and (ii) authorized to consummate the purchase of the Purchased Securities.
	 	 
	(b)	The
    Issuer has provided to it the opportunity to ask questions and receive answers concerning the terms and conditions of the offering
    and it has had access to such information concerning the Issuer as it has considered necessary or appropriate in connection with
    its investment decision to acquire the Purchased Securities, including access to the Issuer’s public filings available on the
    Internet at www.sedar.com, and that any answers to questions and any request for information have been complied with to the Purchaser’s
    satisfaction.
	 	 
	(c)	It
    is purchasing the Purchased Securities for its own account or for the account or benefit of one or more persons for whom it is exercising
    sole investment discretion (a “Beneficial Purchaser”), for investment purposes only and not with a view to resale
    or distribution and, in particular, neither it nor any Beneficial Purchaser for whose account it is purchasing the Purchased Securities
    has any intention to distribute either directly or indirectly any of the Securities in the United States or to U.S. Persons; provided,
    however, that this paragraph shall not restrict the Purchaser from selling or otherwise disposing of any of the Securities pursuant
    to registration thereof pursuant to the Securities Act and any applicable state securities laws or under an exemption from such registration
    requirements.
	 	 
	(d)	The
    address of the Purchaser set out on the execution pages of the Securities Purchase Agreement is the true and correct principal address
    of the Purchaser and can be relied on by the Issuer for the purposes of state blue-sky laws and the Purchaser has not been formed
    for the specific purpose of purchasing the Securities.
	 	 
	(e)	It
    understands (i) the Securities and any Warrant Shares issuable upon exercise of the Warrants have not been and will not be registered
    under the Securities Act or the securities laws of any state of the United States and will be “restricted securities”,
    as defined in Rule 144 under the Securities Act; (ii) the sale contemplated hereby is being made in reliance on an exemption from
    such registration requirements in reliance upon Rule 506(b) of Regulation D and/or section 4(a)(2) under the Securities Act; and
    (iii) subject to certain exceptions provided under the Securities Act, the Purchased Securities and the Warrant Shares may not be
    transferred or exercised in the United States or by or on behalf of a U.S. Person unless such Securities or the Warrant Shares, as
    applicable, are registered under the Securities Act and applicable state securities laws, or unless an exemption from such registration
    requirements is available.
	 	 
	(f)	it,
    and, if applicable, each Beneficial Purchaser for whose account it is purchasing the Securities, is an accredited investor as defined
    in Rule 501(a) of Regulation D under the Securities Act and satisfies one or more of the categories of an accredited investor, as
    indicated below (the Purchaser must initial “SUB” for the Purchaser, and “BP” for each Beneficial Purchaser,
    if any, on the appropriate line(s)):


 




    	 	Sch D-1	 



     


    

 


SCHEDULE
D - CERTIFICATION


OF
U.S. PURCHASER


 


	 	1.
                                            Initials _______
	A
    bank, as defined in Section 3(a)(2) of the Securities Act, whether acting in its individual or fiduciary capacity; or
	 	 	 
	 	2.
    Initials _______	A
    savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Securities Act, whether acting in its individual
    or fiduciary capacity; or
	 	 	 
	 	3.
    Initials _______	A
    broker or dealer registered pursuant to Section 15 of the United States Securities Exchange Act of 1934; or
	 	 	 
	 	4.
    Initials _______	An
    insurance company as defined in Section 2(13) of the Securities Act; or
	 	 	 
	 	5.
    Initials _______	An
    investment company registered under the United States Investment Company Act of 1940; or
	 	 	 
	 	6.
    Initials _______	A
    business development company as defined in Section 2(a)(48) of the United States Investment Company Act of 1940; or
	 	 	 
	 	7.
    Initials _______	A
    small business investment company licensed by the U.S. Small Business Administration under Section 301 (c) or (d) of the United States
    Small Business Investment Act of 1958; or
	 	 	 
	 	8.
    Initials _______	A
    plan established and maintained by a state, its political subdivisions or any agency or instrumentality of a state or its political
    subdivisions, for the benefit of its employees, with total assets in excess of US$5,000,000; or
	 	 	 
	 	9.
    Initials _______	An
    employee benefit plan within the meaning of the United States Employee Retirement Income Security Act of 1974 in which the
    investment decision is made by a plan fiduciary, as defined in Section 3(21) of such Act, which is either a bank, savings and loan
    association, insurance company or registered investment adviser, or an employee benefit plan with total assets in excess of US$5,000,000
    or, if a self-directed plan, with investment decisions made solely by persons who are Accredited Investors; or
	 	 	 
	 	10.
    Initials _______	A
    private business development company as defined in Section 202(a)(22) of the United States Investment Advisers Act of 1940;
    or
	 	 	 
	 	11.
    Initials _______	An
    organization described in Section 501(c)(3) of the United States Internal Revenue Code, a Company, a Massachusetts or similar
    business trust, or a partnership, not formed for the specific purpose of acquiring the Securities offered, with total assets in excess
    of US$5,000,000; or
	 	 	 
	 	12.
    Initials _______	Any
    director or executive officer of the Issuer; or
	 	 	 
	 	13.
    Initials _______	A
    natural person whose individual net worth, or joint net worth with that person’s spouse, at the time of this purchase exceeds
    US$1,000,000; provided, however, that (i) person’s primary residence shall not be included as an asset; (ii) indebtedness that
    is secured by the person’s primary residence, up to the estimated fair market value of the primary residence at the time of
    the sale of securities, shall not be included as a liability (except that if the amount of such indebtedness outstanding at the time
    of the sale of securities exceeds the amount outstanding 60 days before such time, other than as a result of the acquisition of the
    primary residence, the amount of such excess shall be included as a liability); and (iii) indebtedness that is secured by the person’s
    primary residence in excess of the estimated fair market value of the primary residence at the time of the sale of securities shall
    be included as a liability; or


 




    	 	Sch D-2	 



     


    

 



SCHEDULE
                                            D - CERTIFICATION


OF
U.S. PURCHASER



 


	 	14.
    Initials _______	A
    natural person who had an individual income in excess of US$200,000 in each of the two most recent years or joint income with that
    person’s spouse in excess of US$300,000 in each of those years and has a reasonable expectation of reaching the same income
    level in the current year; or
	 	 	 
	 	15.
    Initials _______	A
    trust, with total assets in excess of US$5,000,000, not formed for the specific purpose of acquiring the Securities offered, whose
    purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii) under the Securities Act; or
	 	 	 
	 	16.
    Initials _______	Any
    entity in which all of the equity owners meet the requirements of at least one of the above categories.


 


	(g)	The
    Purchaser has not purchased the Purchased Securities as a result of any form of general solicitation or general advertising (as those
    terms are used in Rule 502(c) of Regulation D under the Securities Act), including advertisements, articles, notices or other communications
    published in any newspaper, magazine, the internet or similar media or broadcast over radio or television or the internet, or other
    form of telecommunications, including electronic display, or any seminar or meeting whose attendees have been invited by general
    solicitation or general advertising.
	 	 
	(h)	If
    the Purchaser decides to offer, sell or otherwise transfer any of the Purchased Securities or the Warrant Shares, it will not offer,
    sell or otherwise transfer any of such Securities directly or indirectly, unless:


 


	 	(i)	the
    sale is to the Issuer;
	 	 	 
	 	(ii)	the
    sale is made outside the United States in a transaction meeting the requirements of Rule 904 of Regulation S under the Securities
    Act and in compliance with applicable local laws and regulations;
	 	 	 
	 	(iii)	if
    the sale is made in Canada, such sale occurs on or after such date which falls four (4) months from the Closing Date;
	 	 	 
	 	(iv)	the
    sale is made pursuant to the exemption from the registration requirements under the Securities Act provided by (a) Rule 144 or (b)
    Rule 144A thereunder, if available, and in accordance with any applicable state securities or “blue sky” laws; or
	 	 	 
	 	(v)	the
    securities are sold in a transaction that does not require registration under the Securities Act or any applicable state laws and
    regulations governing the offer and sale of securities,


 


and,
in the case of each of (iv)(a) and (v) it has prior to such sale furnished to the Issuer an opinion of counsel reasonably satisfactory
to the Issuer stating that such transaction is exempt from registration under applicable securities laws and that the legends referred
to in paragraph (j) below may be removed.


 


	(i)	It
    acknowledges that it has not purchased the Purchased Securities as a result of, and will not itself engage in, any “directed
    selling efforts” (as defined in Rule 902(c) of Regulation S under the Securities Act) in the United States in respect of
    the Purchased Securities which would include any activities undertaken for the purpose of, or that could reasonably be expected to
    have the effect of, conditioning the market in the United States for the resale of the Purchased Securities or the Warrant Shares.
	 	 
	(j)	The
    certificates representing the Purchased Securities issued hereunder and any Warrant Shares issued upon exercise of the Warrants,
    as well as all certificates issued in exchange for or in substitution of the foregoing, until such time as is no longer required
    under the applicable requirements of the Securities Act or applicable state securities laws, will bear, on the face of such certificate,
    the following legends:


 




    	 	Sch D-3	 



     


    

 



SCHEDULE
                                            D - CERTIFICATION


OF
U.S. PURCHASER



 


“THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”) OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR
THE BENEFIT OF WESTERN MAGNESIUM CORP. (THE “COMPANY”) THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED ONLY (A) TO THE COMPANY; (B) OUTSIDE THE UNITED STATES, IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE SECURITIES
ACT AND IN COMPLIANCE WITH APPLICABLE LOCAL LAWS AND REGULATIONS; (C) PURSUANT TO THE EXEMPTION FROM REGISTRATION UNDER THE SECURITIES
ACT PROVIDED RULE 144 UNDER THE SECURITIES ACT, IF AVAILABLE, AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS; (D) IN ANOTHER
TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS, PROVIDED THAT IN THE
CASE OF TRANSFERS PURSUANT TO (C) OR (D) ABOVE, THE SELLER FURNISHES TO THE COMPANY AN OPINION OF COUNSEL OF RECOGNIZED STANDING IN FORM
AND SUBSTANCE SATISFACTORY TO THE COMPANY TO SUCH EFFECT.”


 


provided,
that if the Common Shares are being sold outside the United States in compliance with the requirements of Rule 904 of Regulation S, the
legends set forth above may be removed by providing an executed declaration to the registrar and transfer agent of the Company, in substantially
the form set forth as Appendix A attached hereto (or in such other forms as the Company may prescribe from time to time) and, if requested
by the Company or the transfer agent, an opinion of counsel of recognized standing in form and substance satisfactory to the Company
and the transfer agent to the effect that such sale is being made in compliance with Rule 904 of Regulation S; and provided, further,
that, if any Common Shares, are being sold otherwise than in accordance with Regulation S and other than to the Company, the legend may
be removed by delivery to the registrar and transfer agent and the Company of an opinion of counsel, of recognized standing reasonably
satisfactory to the Company, that such legend is no longer required under applicable requirements of the U.S. Securities Act or state
securities laws. It understands and agrees that the Warrants may not be exercised in the United States or by or on behalf of a U.S. person
or a person in the United States unless registered under the Securities Act and any applicable state securities laws or unless an exemption
from such registration requirements is available and the holder has furnished an opinion of counsel of recognized standing in form and
substance satisfactory to the Issuer to such effect, and that certificates representing the Warrants will bear a legend to the following
effect in addition to the legend stated in clause (l) of this Certificate of U.S. Purchaser:


 


“THE
SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED
STATES SECURITIES ACT OF 1933, AS AMENDED (THE “U.S.
SECURITIES ACT”), OR THE LAWS OF ANY STATE OF THE UNITED STATES. THE HOLDER HEREOF, BY PURCHASING
SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE COMPANY THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY
(A) TO THE COMPANY, (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT AND IN COMPLIANCE
WITH APPLICABLE LOCAL LAWS AND REGULATIONS, (C) IN COMPLIANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT PROVIDED
BY (1) RULE 144 THEREUNDER, IF AVAILABLE, OR (2) RULE 144A THEREUNDER, IF AVAILABLE, AND, IN BOTH CASES, IN ACCORDANCE WITH APPLICABLE
STATE SECURITIES LAWS OR (D) IN ANOTHER TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT OR ANY APPLICABLE
STATE SECURITIES LAWS AND, IN THE CASE OF (C)(1) AND (D) ABOVE, AFTER THE SELLER FURNISHES TO THE COMPANY AN OPINION OF COUNSEL OF RECOGNIZED
STANDING OR SUCH OTHER EVIDENCE IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY TO SUCH EFFECT. DELIVERY OF THIS CERTIFICATE
MAY NOT CONSTITUTE “GOOD DELIVERY” IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA. A NEW CERTIFICATE BEARING
NO LEGEND, DELIVERY OF WHICH WILL CONSTITUTE “GOOD DELIVERY”, MAY BE OBTAINED FROM THE TRANSFER AGENT AND REGISTRAR OF THE
COMPANY UPON DELIVERY OF THIS CERTIFICATE AND A DULY EXECUTED DECLARATION, IN A FORM SATISFACTORY TO THE TRANSFER AGENT AND REGISTRAR
OF THE COMPANY AND THE COMPANY, TO THE EFFECT THAT THE SALE OF THE SECURITIES REPRESENTED HEREBY IS BEING MADE IN COMPLIANCE WITH RULE
904 OF REGULATION S UNDER THE U.S. SECURITIES ACT.”


 




    	 	Sch D-4	 



     


    

 



SCHEDULE
                                            D - CERTIFICATION


OF
U.S. PURCHASER



 


	(k)	It
    understands and agrees that there may be material tax consequences to the Purchaser of an acquisition, disposition or exercise of
    any of the Purchased Securities. The Issuer gives no opinion and makes no representation with respect to the tax consequences to
    the Purchaser under United States, state, local or foreign tax law of the undersigned’s acquisition or disposition of such
    Securities; in particular, no determination has been made whether the Issuer will be a “passive foreign investment company”
    within the meaning of Section 1297 of the United States Internal Revenue Code.
	 	 
	(l)	It
    understands and acknowledges that the Issuer is incorporated outside the United States. Consequently, it may be difficult to provide
    service of process on the Issuer and it may be difficult to enforce any judgment against the Issuer.
	 	 
	(m)	It
    understands and agrees that the financial statements of the Issuer have been prepared in accordance with International Financial
    Reporting Standards and therefore may be materially different from financial statements prepared under U.S. generally accepted accounting
    principles and therefore may not be comparable to financial statements of United States companies.
	 	 
	(n)	It
    consents to the Issuer making a notation on its records or giving instructions to any transfer agent of the Issuer in order to implement
    the restrictions on transfer set forth and described in this certification and the Securities Purchase Agreement.
	 	 
	(o)	It
    understands and acknowledges that the Issuer is not obligated to become a “foreign issuer” (as defined in Rule
    902(e) of Regulation S).
	 	 
	(p)	It
    understands, that the funds representing the Aggregate Purchase Price which will be advanced by the Purchaser to the Issuer hereunder
    will not represent proceeds of crime for the purposes of the Uniting and Strengthening America by Providing Appropriate Tools
    Required to Intercept and Obstruct Terrorism Act (the “PATRIOT Act”) and the Purchaser acknowledges that the
    Issuer may in the future be required by law to disclose the Purchaser’s name and other information relating to the Securities
    Purchase Agreement and the Purchaser’s subscription hereunder, on a confidential basis, pursuant to the PATRIOT Act. No portion
    of the Aggregate Purchase Price to be provided by the Purchaser (i) has been or will be derived from or related to any activity that
    is deemed criminal under the laws of the United States, or any other jurisdiction, or (ii) is being tendered on behalf of a person
    or entity who has not been identified to or by the Purchaser, and it shall promptly notify the Issuer if the Purchaser discovers
    that any of such representations ceases to be true and provide the Issuer with appropriate information in connection therewith.


 




    	 	Sch D-5	 



     


    

 




SCHEDULE
                                            D - CERTIFICATION


OF
U.S. PURCHASER



 


	(q)	It
    has no intention to distribute, and shall not transfer, either directly or indirectly, any of the Securities to any person within
    the United States or to U.S. persons except pursuant to an effective registration statement under the Securities Act, or an exemption
    therefrom.


 


Dated
____________________, 2021.


 


	 	X	         
	 	Signature
    of individual (if Purchaser is an individual)
	 	 
	 	X	 
	 	Authorized
    signatory (if Purchaser is not an individual)
	 	 
	 	 
	 	Name
    of Purchaser (please print)
	 	 
	 	 
	 	Name
    of authorized signatory (please print)
	 	 
	 	 
	 	Official
    capacity of authorized signatory (please print)


 




    	 	Sch D-6	 



     


    

 


Appendix
“A” to Schedule D


 


CERTIFICATE
OF U.S. PERSON


 


Form
of Declaration for Removal of Legend


 


	TO:	WESTERN
    MAGNESIUM CORP. (the “Company”)
	 	 
	TO:	Registrar
    and transfer agent for the shares of the Company


 


The
undersigned (A) acknowledges that the sale of the securities of the Company to which this declaration relates is being made in reliance
on Rule 904 of Regulation S under the United States Securities Act of 1933, as amended (the “Securities
Act”), and (B) certifies that (1) the undersigned is not (a) an “affiliate”
of the Company (as that term is defined in Rule 405 under the Securities Act) (b) a “distributor”
as defined in Regulation S or (c) an affiliate of a distributor; (2) the offer of such securities was not made to a person in the United
States and either (a) at the time the buy order was originated, the buyer was outside the United States, or the seller and any person
acting on its behalf reasonably believed that the buyer was outside the United States, or (b) the transaction was executed on or through
the facilities of the TSX Venture Exchange and neither the seller nor any person acting on its behalf knows that the transaction has
been prearranged with a buyer in the United States; (3) neither the seller nor any affiliate of the seller nor any person acting on their
behalf has engaged or will engage in any directed selling efforts in the United States in connection with the offer and sale of such
securities; (4) the sale is bona fide and not for the purpose of “washing off” the
resale restrictions imposed because the securities are “restricted securities” (as
that term is defined in Rule 144(a)(3) under the Securities Act); (5) the seller does not intend to replace such securities with fungible
unrestricted securities; and (6) the contemplated sale is not a transaction, or part of a series of transactions, which, although in
technical compliance with Regulation S, is part of a plan or scheme to evade the registration provisions of the U. S. Securities Act.
Terms used herein have the meanings given to them by Regulation S under the Securities Act.


 


	DATED
     _______________ 20__	X	        
	 	Signature
    of individual (if Purchaser is an individual)
	 	 
	 	X	 
	 	Authorized
    signatory (if Purchaser is not an individual)
	 	 
	 	 
	 	Name
    of Purchaser (please print)
	 	 
	 	 
	 	Name
    of authorized signatory (please print)
	 	 
	 	 
	 	Official
    capacity of authorized signatory (please print)


 




    	 	Sch D-7	 



     


    

 


	Schedule
                                            E

                                           APPENDIX
                                           6B
	



 


ACKNOWLEDGEMENT
– PERSONAL INFORMATION


 


TSX
Venture Exchange Inc. and its affiliates, authorized agents, subsidiaries and divisions, including the TSX Venture Exchange (collectively
referred to as “the Exchange”) collect Personal Information in certain Forms that are submitted by the individual and/or
by an Issuer or Applicant and use it for the following purposes:


 


	 	●	to
    conduct background checks,
	 	 	 
	 	●	to
    verify the Personal Information that has been provided about each individual,
	 	 	 
	 	●	to
    consider the suitability of the individual to act as an officer, director, insider, promoter, investor relations provider or, as
    applicable, an employee or consultant, of the Issuer or Applicant,
	 	 	 
	 	●	to
    consider the eligibility of the Issuer or Applicant to list on the Exchange,
	 	 	 
	 	●	to
    provide disclosure to market participants as to the security holdings of directors, officers, other insiders and promoters of the
    Issuer, or its associates or affiliates, and includes information as to such individual’s involvement with any other reporting
    issuers, issuers subject to a cease trade order or bankruptcy, as well as information respecting penalties, sanctions or personal
    bankruptcies, to which such individual has been subject, as well as any conflicts of interest that the individual may have with the
    Issuer,
	 	 	 
	 	●	to
    detect and prevent fraud,
	 	 	 
	 	●	to
    conduct enforcement proceedings, and
	 	 	 
	 	●	to
    perform other investigations as required by and to ensure compliance with all applicable rules, policies, rulings and regulations
    of the Exchange, securities legislation and other legal and regulatory requirements governing the conduct and protection of the public
    markets in Canada.


 


As
part of this process, the Exchange also collects additional Personal Information from other sources, including but not limited to, securities
regulatory authorities in Canada or elsewhere, investigative, law enforcement or self-regulatory organizations, regulations services
providers and each of their subsidiaries, affiliates, regulators and authorized agents, to ensure that the purposes set out above can
be accomplished.


 


The
Personal Information the Exchange collects may also be disclosed:


 


	(a)	to
    the agencies and organizations in the preceding paragraph, or as otherwise permitted or required by law, and they may use it in their
    own investigations for the purposes described above; and
	 	 
	(b)	on
    the Exchange’s website or through printed materials published by or pursuant to the directions of the Exchange.


 


The
Exchange may from time to time use third parties to process information and/or provide other administrative services. In this regard,
the Exchange may share the information with such third party service providers.


 




    	 	Sch E-1	 



     


    

 


SCHEDULE
3.1(a)

SUBSIDIARIES


 


	Subsidiary	 	Jurisdiction
    of Existence	 	Percentage
    of Ownership
	Western
    Magnesium Corp. 	 	Nevada,
    USA	 	100%
	Western
    Magnesium Canada Corp.	 	British
    Columbia, Canada	 	100%


 


 




    	 



     


    

 


SCHEDULE
3.1(g)

CAPITALIZATION


 


The
authorized capital of the Corporation consists of 1,000,000,000 voting shares of common stock at par value of $0.001, of which 429,748,992
shares of Common Stock are issued and outstanding as of the date hereof.


 


The
Corporation currently has [58,760,000] stock options and [38,847,619] share purchase warrants issued and outstanding.


 


The
Corporation also has as an unsecured convertible note in the principal amount of US$1,100,000 (the “June 2021 Convertible Debenture”)
outstanding. The June 2021 Convertible Debenture bears interest at 12% per annum and is due on December 10, 2022. The June 2021 Convertible
Debenture is convertible into units of the Corporation at a price of US$0.10 per unit, with each unit being comprised of (i) one share
of Common Stock, (ii) one-half of a Class A common stock warrant, with each whole warrant being exercisable at a price of US$0.13 until
June 10, 2026; and (iii) one-half of a Class B common stock warrant, with each whole warrant being exercisable at a price of US$0.19
until June 10, 2026. In addition, the conversion price for accrued interest is the greater of (i) $0.10 and (ii) the minimum conversion
price permitted by the TSX Venture Exchange at the time of conversion.


 


The
Corporation also has as an unsecured convertible note in the principal amount of Cdn$100,000 (the “July 2021 Convertible Debenture”)
outstanding. The July 2021 Convertible Debenture bears interest at 12% per annum and is due on April 22, 2022. The July 2021 Convertible
Debenture is convertible into units of the Corporation at a price of Cdn$0.12 per unit, with each unit being comprised of (i) one share
of Common Stock and (ii) one common stock warrant exercisable at a price of Cdn$0.20 for a period of 2 years. Any accrued but unpaid
interest will be payable on the earlier of the maturity date and the date of conversion in cash or in common shares (subject to receipt
of regulatory approval).


 




    	 



     


    

 


SCHEDULE
3.1(i)

MATERIAL CHANGES; UNDISCLOSED EVENTS, LIABILITIES OR DEVELOPMENTS


 


Not
applicable.


 




    	 



     


    

 


SCHEDULE
3.1(j)

litigation 


 


A
Notice of Civil Claim has been filed in the Supreme Court of British Columbia on September 30, 2020 by Jim Sever. Mr. Sever has claimed
for upwards of US$2 million in severance and severance-type damages.


 


On
December 31, 2020, GEM Yield Bahamas Limited (“GEM”) served the Company with a Notice of Intention to Arbitrate (the “New
York Arbitration Notice”) before the American Arbitration Association in New York (the “GEM New York Arbitration”).
The New York Arbitration Notice alleges the Company breached a Share Subscription Agreement dated November 15, 2019 entered into between
the Company and GEM (the “GEM Agreement”), among other things, claiming damages of CA$4.2 million (USD equivalent $3.4 million).
On January 19, 2021, the Company filed a petition in the New York Supreme Court to stay the GEM New York Arbitration claiming the GEM
Agreement was not valid. On March 19, 2021, the Court in the New York State Action ruled that there was an arbitration clause in the
GEM Agreement but it was up to the arbitrator to determine if the arbitration clause was valid. Following this ruling, the New York State
Action was closed. In June 2021, GEM filed a Statement of Claim in the GEM New York Arbitration, and the Company filed a Statement of
Answer denying the existence of any binding agreement between the Company and GEM, among other defenses. In January 2022, the Company
filed a Modified Statement of Defense and Counterclaims. The Company intends to vigorously defend itself in the GEM New York Arbitration
and believes the allegations lack merit.


 


On
February 8, 2021, GEM instituted another arbitration against the Company before the International Centre for Dispute Resolution in Montreal
Canada (the “GEM Montreal Arbitration”) and joined GEM’s affiliate, GEM Global Yield LLC SCS (“GEM Global Yield”
together with GEM, the “GEM Parties”). The Statement of Claim filed by the GEM Parties alleges the Company breached a Share
Subscription Agreement dated November 15, 2019 and promissory note, among other things, claiming damages of approximately CA$4.9 million
(USD equivalent $3.9 million), in addition to costs and expenses, stemming from the Company’s alleged failure to issue to GEM Global
Yield warrants to purchase up to 33 million shares of the Company’s common stock. The Company filed a Statement of Defense denying
the existence of any binding agreement between the Company and GEM, among other defenses. In January 2022, the Company filed an Amended
Statement of Defense and Cross-claim. The Company intends to vigorously defend itself in the GEM Montreal Arbitration and believes the
allegations lack merit. 


 


On
April 19, 2021, Lampert Advisors, LLC (“Lampert”) filed a Verified Complaint against the Company’s wholly owned subsidiary
Western Magnesium Corp., a Nevada corporation (“Western Magnesium – Nevada”) in the Supreme Court of the State of New
York, County of New York (the “Lampert Lawsuit”). The complaint filed in the Lampert Lawsuit alleges that Lampert entered
into an agreement with Western Magnesium – Nevada to provide various financial advisory services including acquisition advisory
services and act as an exclusive placement agent for a combination of debt and equity securities (the “Lampert Agreement”),
that it performed all services required under that agreement and that it is owed $367,227 plus interest at the rate of 9% from February
3, 2021 and that it has a right of first refusal to act as financial advisor in connection with any debt, equity or debt restructuring
assignments on terms, conditions and compensation customary for Lampert for a transaction of the type contemplated. Although Lampert
claims to have personally served Western Magnesium – Nevada, the Company never received the Summons and Complaint and therefore,
neversubmitted a response. On September 9, 2021, Lampert filed a Motion seeking the entry of a default judgment (the “Motion”).
The Company opposed the Motion and filed a cross-motion to compel Lampert to accept the Company’s answer. The Court granted the
Company’s cross-motion and denied Lampert’s Motion as moot. The Court scheduled a preliminary conference for the parties
on March 30, 2022. The Company intends to vigorously defend against the Lampert Lawsuit, and believes that the Lampert Lawsuit is without
merit.


 




    	 



     


    

 


SCHEDULE
3.1(z)

SOLVENCY


 


The
outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments,
are as follows:


 


The
Corporation has as an unsecured convertible note in the principal amount of US$1,100,000 (the “June 2021 Convertible Debenture”)
outstanding. The June 2021 Convertible Debenture bears interest at 12% per annum and is due on December 10, 2022. The June 2021 Convertible
Debenture is convertible into units of the Corporation at a price of US$0.10 per unit, with each unit being comprised of (i) one share
of Common Stock, (ii) one-half of a Class A common stock warrant, with each whole warrant being exercisable at a price of US$0.13 until
June 10, 2026; and (iii) one-half of a Class B common stock warrant, with each whole warrant being exercisable at a price of US$0.19
until June 10, 2026. In addition, the conversion price for accrued interest is the greater of (i) $0.10 and (ii) the minimum conversion
price permitted by the TSX Venture Exchange at the time of conversion.


 


The
Corporation also has as an unsecured convertible note in the principal amount of Cdn$100,000 (the “July 2021 Convertible Debenture”)
outstanding. The July 2021 Convertible Debenture bears interest at 12% per annum and is due on April 22, 2022. The July 2021 Convertible
Debenture is convertible into units of the Corporation at a price of Cdn$0.12 per unit, with each unit being comprised of (i) one share
of Common Stock and (ii) one common stock warrant exercisable at a price of Cdn$0.20 for a period of 2 years. Any accrued but unpaid
interest will be payable on the earlier of the maturity date and the date of conversion in cash or in common shares (subject to receipt
of regulatory approval).


 




    	 



     


    

 


SCHEDULE
3.1(ll)

INDEBTEDNESS AND SENIORITY


 


The
outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments,
are as follows:


 


The
Corporation has as an unsecured convertible note in the principal amount of US$1,100,000 (the “June 2021 Convertible Debenture”)
outstanding. The June 2021 Convertible Debenture bears interest at 12% per annum and is due on December 10, 2022. The June 2021 Convertible
Debenture is convertible into units of the Corporation at a price of US$0.10 per unit, with each unit being comprised of (i) one share
of Common Stock, (ii) one-half of a Class A common stock warrant, with each whole warrant being exercisable at a price of US$0.13 until
June 10, 2026; and (iii) one-half of a Class B common stock warrant, with each whole warrant being exercisable at a price of US$0.19
until June 10, 2026. In addition, the conversion price for accrued interest is the greater of (i) $0.10 and (ii) the minimum conversion
price permitted by the TSX Venture Exchange at the time of conversion.


 


The
Corporation also has as an unsecured convertible note in the principal amount of Cdn$100,000 (the “July 2021 Convertible Debenture”)
outstanding. The July 2021 Convertible Debenture bears interest at 12% per annum and is due on April 22, 2022. The July 2021 Convertible
Debenture is convertible into units of the Corporation at a price of Cdn$0.12 per unit, with each unit being comprised of (i) one share
of Common Stock and (ii) one common stock warrant exercisable at a price of Cdn$0.20 for a period of 2 years. Any accrued but unpaid
interest will be payable on the earlier of the maturity date and the date of conversion in cash or in common shares (subject to receipt
of regulatory approval).


 




    	 



     


    

 


SCHEDULE
4.9


USE
OF PROCEEDS


 


The
Company intends to use the proceeds from Offering for working capital and corporate purposes, and to repay the principal and accrued
interest owing pursuant to the July 2021 Convertible Debenture.